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 Infections in patients with acute liver failure (ALF) and acute liver injury (ALI) 
are a frequent occurrence.  Because ALF and ALI patients share many of the same 
clinical features as patients with severe sepsis and septic shock, identifying an infection 
based upon clinical manifestations is extremely difficult.  Bacterial culture and sensitivity 
reports require 24 to 72 hours to be finalized after the need for a culture is suspected and 
obtained. During this time period, ALF and ALI patients are either not receiving required 
antibiotic therapy, receiving antibiotic therapy that is not required or not appropriate for 
the infecting bacterial pathogen, or receiving the correct antibiotic prophylaxis.  
Receiving an antibiotic that is not needed or inappropriate adds another level of 
complexity to the ALF and ALI patients because antibiotics may exacerbate liver 
dysfunction.  
  
 
 The purpose of this study was to determine the utility of serum procalcitonin 
concentrations (SPCTC) as a biomarker of bacterial infections in patients with acute liver 
failure (ALF) and acute liver injury (ALI). This three part study measured SPCTC 
retrospectively on samples from ALF and ALI patients who were prospectively enrolled 
in the United States Acute Liver Failure Study Group (USALFSG) ALF and ALI studies. 
In the first part of the study, subjects were categorized according to how many SIRS 
continuum components they had and whether there was a documented infection. In the 
second part, serial samples on subjects who developed infections were identified. And, in 
the third part, serial samples on subjects diagnosed with infection on day one of the study 
and categorized based upon transplant free survival (TFS) or death and/or liver transplant 
(DoT) were identified.  
 Procalcitonin was not found to be useful in identifying infection in the ALF and 
ALI patient populations. A cut-off for indication of infection was calculated to be 1.62 
ng/mL using receiver operator curve (ROC) analysis. Despite the fact that there was an 
overall increase in SPCTC as the severity of illness increased in patients with a 
documented infection, there were confounding variables including antibiotic use, missing 
data, and small sample size that may have contributed to the poor sensitivity and 
specificity (0.643 and 0.620 respectively) calculated as part of the ROC analysis.  
SPCTC values appeared to be increased in subject with acetaminophen (APAP) 
toxicity and may have affected the cut-off, sensitivity, and specificity results. Increased 
SPCTC values were seen in APAP subjects who did not have a documented infection. It 
  
 
is unknown at this time if the SPCTC were increase due to liver damage, an undiagnosed 
infection, or as a result of increase cytokine production due to the APAP toxicity.  
Serial PCT concentrations in patients who achieved TFS showed a greater 
decrease over time than those of patients who died or received a liver transplant, 
however, the TFS group contained a large portion of APAP subjects. Further prospective 
studies are needed to determine the extent of interference with SPCTC in patients with 
APAP toxicity and to better define the PCT concentration cut-off between infection and 
no infection in the ALF and ALI populations. 
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CHAPTER 1:  INTRODUCTION 
 
 Infections are a frequent occurrence in patients diagnosed with acute liver failure 
(ALF) and acute liver injury (ALI). Overall mortality in patients with ALF has been 
estimated at 30 – 40%. Approximately 44% of ALF patients are listed for liver 
transplantation with 12 – 25% of all ALF patients receiving a liver transplant (Bower, 
Johns, Margolis, Williams, & Bell, 2007; Lee, Squires, Nyberg, Doo, & Hoofnagle, 
2008). Bacterial infections are reported to occur in 40% - 90% of ALF patients (Rolando 
et al., 2000; Vaquero et al., 2003). The mortality rate due to bacterial infection (or 
suspected bacterial infection) in the general population increases from approximately 
10% in patients with systemic inflammatory response syndrome (SIRS), to approximately 
50% in patients with septic shock (Brun-Buisson, 2000; Rangel-Frausto et al., 1995). 
ALF has many of the same characteristics of septic shock and the presence of SIRS in 
ALF is associated with a poor prognosis (Antoniades, Berry, Wendon, & Vergani, 2008).  
Studies have shown a link between bacterial infection and increasing mortality in ALF 
(Rolando et al., 1990; Rolando et al., 2000). Another study has indicated a relationship 
between bacterial infection and the progression to stage III-IV hepatic encephalopathy 
(HE) and a decrease in spontaneous (survival without liver transplant) survival (Vaquero 
et al., 2003). However, there are no studies specifically looking at bacterial infection in 
the ALF population related to the SIRS spectrum and to clinical outcome. Currently, 
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methods to detect and identify bacterial infections and antibiotic sensitivities require at 
least 24 to 72 hours to produce results. Furthermore, cultures may be negative even if an 
infection is present (Fenollar & Raoult, 2007). Various methods utilizing molecular 
techniques have been developed in an effort to speed up and/or improve identification of 
infection-causing bacteria. While these techniques may improve the time to result for 
organisms that require longer incubation periods (days to weeks) to grow and isolate, the 
techniques do not improve the time to result for pathogens requiring shorter incubation 
periods (24 – 48 hours) to grow and isolate (Sabet, Subramaniam, Navaratnam, & 
Sekaran, 2006; Stefani, 2009).  
 A biomarker that can provide an immediate determination that a bacterial 
infection is present and can give an indication of severity would provide a major 
improvement in the ability to treat ALF and ALI patients who have a bacterial infection.  
Procalcitonin (PCT) is a biomarker of inflammatory response that requires one to two 
hours to obtain a result and tends to increase with the severity of the infection. Studies 
indicate that elevated PCT values are associated with most types of bacterial infections 
(Brunkhorst, Wegscheider, Forycki, & Brunkhorst, 2000; P. E. Charles et al., 2008; 
Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M. M., Huber, P. R., Tamm, 
M., et al. (2004).  PCT has a half-life of 25 to 30 hours suggesting that a short-term rise 
or fall in the serum PCT concentration (SPCTC) could be indicative of a change in a 
patient’s infection status. The PCT molecule is stable in serum or plasma samples for up 
to 24 hours at 4
o
C, making accurate measurement of PCT feasible. SPCTC is a potential 
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candidate for measurement in the clinical laboratory to monitor patients for bacterial 
infection and sepsis (Jin & Khan, 2010).  
 In studies in patients with sepsis, pneumonia, and other types of infections, PCT 
has been shown to be a good indicator of bacterial infection and a useful tool in guiding 
antimicrobial therapy (Muller, Christ-Crain, & Schuetz, 2007). In patients with liver 
disease, PCT has been examined in patients who have had liver transplant and in patients 
hospitalized with chronic liver disease (cirrhosis), but there are no studies of patients with 
ALF or ALI (Elefsiniotis et al., 2006). 
Purpose of This Study 
The purpose of the study was to retrospectively examine the levels of PCT in 
patients with ALF and ALI with and without evidence of bacterial infection to determine 
the usefulness of procalcitonin as a biomarker of infection in ALF and ALI patients. The 
U.S. Acute Liver Failure Study Group (USALFSG) maintains ALF and ALI databases to 
prospectively collect clinical information about ALF and ALI that is used to conduct 
clinical trials aimed at improving treatment for ALF and ALI patients. The USALFSG 
was established in 1998 with pilot funding from the FDA and is currently supported by 
the National Institute of Health (NIH).  
The ALF/ALI databases include 632 documented cases of infection (248 blood, 
304 urine, 49 catheter, 21 wound, 17 ascites, 238 tracheal aspirates, and 48 others (source 
not specified)) from a total of 1829 patients. This study examined the utility of SPCTC as 
an indicator of bacterial infection in ALF/ALI patients.  
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Specific Aims 
There were three main aims for this study: 
Specific Aim 1:  To determine if there are differences in SPCTCs between non-
infected ALF and ALI patients and non-infected chronic liver disease patients, 
between infected and non-infected ALF and ALI patients, and between ALF and 
ALI patients with different severities of infection and those published for the 
general population. 
This was determined by measuring SPCTCs from sera that were collected from ALF and 
ALI patients who were prospectively enrolled in the ALF and ALI studies with a 
documented history of infection, ALF and ALI patients without an infection, and chronic 
liver disease patients without an infection. Chronic liver disease subjects were 
prospectively enrolled in one of two investigator-initiated databases maintained at the 
University of Texas Southwestern Medical Center (UTSW):  The Liver Disease Database 
and the Nucleic Acid, Serum, and Tissue Repository for the Study of Liver Diseases 
(NSTLD). The results were analyzed according to etiology of liver disease, the presence 
or absence of infection, and the severity infection based upon clinical signs and 
symptoms. 
 Specific Aim 2:  Determine the utility of SPCTC as a screening biomarker for 
 infection in ALF and ALI patients 
SPCTC was measured in sera collected on the three days prior to diagnosis of infection 
and on the day an infection was identified (i.e., the day a positive culture was obtained), 
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to determine whether PCT will allow an earlier indication of infection than clinical 
symptoms or culture findings. 
Specific Aim 3:  Determine if SPCTC in ALF and ALI patients with bacterial 
infection on Day 1 of the ALF or ALI study is associated with patient outcomes. 
SPCTCs were measured in serial samples from ALF and ALI patients with known 
infections, to determine whether there are differences in the SPCTCs between patients 
with unfavorable outcomes (death or transplant) and those with favorable outcomes 
(transplant free survival).   
Summary 
 Infection in ALF and ALI patients is a serious complication that may be difficult 
to detect because ALF and ALI subjects have clinical manifestations that are similar to 
septic shock. In addition, reports of bacterial cultures require 24 – 72 hours before they 
are available to the clinician.   
 SPCTC has been proposed as a biomarker of infection/sepsis that can reduce the 
time needed to detect bacterial infections and thereby allow earlier initiation of 
antimicrobial therapy. Multiple studies show that SPCTC has good sensitivity for 
detection of bacterial infection and indicate that SPCTC can decrease the length of 
antibiotic treatment. While there are multiple studies relating SPCTC to the detection of 
infection, there have only been a few studies on patients with chronic liver disease and 
none on ALF or ALI patient populations. In this study, the efficiency of SPCTC to detect 
infection and to predict outcomes in ALF and ALI patients was investigated.
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CHAPTER 2: LITERATURE REVIEW 
 
 The following chapter will present background information relevant to 
procalcitonin, acute liver failure and injury, the pathophysiology of infection and sepsis, 
and the need to identify infections quickly.  First, a description of procalcitonin, its 
origin, and its use as a biomarker for detecting and monitoring treatment of infection and 
sepsis will be presented. Next, information describing acute liver failure and acute liver 
injury and the need for a rapid determination of infection or sepsis in these populations 
will be presented. Next, information describing the pathophysiology of infection and 
sepsis will be presented. An overview of current methods for the diagnosis of bacterial 
infection and the strengths and weaknesses of these methods will be presented. Finally, 
background relating to the rationale for using procalcitonin to detect and monitor 
treatment of infection and sepsis in patients with acute liver failure or injury will be 
discussed.  
Liver Structure and Physiology 
 The liver is composed of single cell thick sheets of hepatocytes arrayed around 
the central vein forming a hexagon. The hepatocyte sheets are separated by sinusoidal 
spaces that contain the Kupffer cells, endothelial cells, and stellate cells. The sinusoidal 
spaces allow blood flow from the hepatic artery and portal vein to the central vein. The 
canaliculi between the hepatocytes drain into ductules that empty into the bile duct. The 
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hepatic artery, portal vein, and bile duct are located in the portal tracts located in the 
corners of the hexagons (Khalili, Liao, & Nquyen, 2010).  
 Hepatocytes compose approximately 80% of the total number of liver cells in an 
adult liver. Hepatocytes are the “metabolic factories” of the liver and are involved in 
carbohydrate, fat, and protein metabolism as well as the production of bile. An important 
feature of the hepatocyte is its ability to regenerate if a portion of the liver is lost or 
removed (Barrett, 2006). 
 Kupffer cells, which develop from the macrophage lineage, line the sinusoidal 
endothelium on the blood stream side of these cells and have highly active phagocytic 
properties, scavenging colonic bacteria that enter the bloodstream from the intestines by 
way of the portal vein. Activation of Kupffer cells by host or foreign antibodies may 
result in the production of cytokines and other inflammatory mediators that contribute to 
liver injury (Barrett, 2006). 
 Endothelial cells lining the hepatic sinusoids have a unique structure that allows 
macromolecules (such as albumin bound with various substances) produced by the 
hepatocytes, to move out of the cells into the blood stream while preventing formed 
elements in the blood (e.g., red blood cells, white blood cells, and platelets) from entering 
the hepatocytes. The structure also allows remnant macromolecules back into the 
hepatocyte. The structure of the sinusoidal endothelial cells is contractile and is 
controlled in part by various hormones and neurotransmitters. If the sinusoidal 
endothelial cells are damaged, passage of these macromolecules into the hepatocyte can 
be disrupted (Barrett, 2006). 
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 Stellate cells store a variety of lipids, the most predominant of which is vitamin A. 
Stellate cells play a major role in liver injury by responding to inflammatory cytokines. 
When activated, the stellate cells lose their stores of vitamin A and up-regulate the 
production of extra-cellular matrix materials, such as collagen, which is deposited in the 
space between the hepatocytes and the sinusoidal endothelial cells, causing a disruption 
of hepatic function and leading to cirrhosis (Barrett, 2006).   
 Liver disease (acute or chronic) may result from impairment or death of one or 
any combination of the liver cell types. Liver function tests are the most commonly used 
method to assess liver injury. Liver function tests include measurement of serum 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-
glutamyltransferase (GGT), alkaline phosphatase (ALP), albumin, total and direct 
bilirubin, and plasma prothrombin time (PT) [converted to international normalized ratio 
(INR)] and ammonia. Liver function tests may be abnormal due to death of the 
hepatocytes (AST, ALT), failure of the liver to secrete bile called cholestasis (bilirubin, 
GGT, ALP), or disruption of metabolic and synthetic functions (PT/INR, ammonia, 
albumin). The degree to which the individual liver function tests are affected depends 
upon which cellular structures or functions are damaged and the amount of damage that 
occurs (Khalili et al., 2010; Merriman & Peters, 2003; Moseley, 2003; Barrett, 2006).  
 As the degree of damage to the liver increases and ammonia levels rise, hepatic 
encephalopathy (HE) may occur. While the pathophysiology of HE is not completely 
understood, what is known is that the disruption of the urea cycle in the liver leads to an 
increase in ammonia and other toxins. In ALF, massive astrocyte swelling and cerebral 
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edema due to an increase in glutamine production characterize HE and increased 
vasodilation possibly due to systemic release of gut-derived endotoxins, pro-
inflammatory cytokines, and stimulation of nitric oxide synthase. As blood ammonia 
levels increase, cerebral ammonia levels also rise due to an impaired blood brain barrier 
(BBB) as the result of vasodilation. Increasing cerebral ammonia levels lead to the 
increased production of glutamine from glutamate by glutamine synthetase in the 
astrocyte, which is the only cell in the brain that contains this enzyme. Increased 
glutamine production results in astrocyte swelling. As the astrocytes swell, more 
ammonia is allowed to cross the BBB increasing the glutamine levels further and 
eventually resulting in cerebral edema and ultimately death by cerebral herniation 
(Barrett, 2006; Mendler, Donovan, & Blei, 2003). 
Acute Liver Failure and Acute Liver Injury 
 Acute liver failure is characterized by severe liver cell dysfunction that occurs 
suddenly in patients with no known underlying liver disease. It is also known as 
fulminant hepatitis or fulminant hepatic failure. Although ALF was first described as a 
specific disease in the early 1950s, it was not until 1970 that it was defined as fulminant 
hepatic failure including HE. HE is cerebral dysfunction without structural abnormalities 
in the presence of liver disease. The extent of the dysfunction is graded (West Haven 
criteria grades) I – IV where grade I represents minimal dysfunction (trivial lack of 
awareness or shortened attention span) and grade IV represents coma (unresponsive to 
stimuli) (Ferenci et al., 2002; Trey & Davidson, 1970). The definition of ALF has been 
revised to include certain chronic liver diseases that can present as ALF but in retrospect, 
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have been present but unrecognized, specifically Wilson’s Disease and hepatitis B. These 
two diseases are unique in having very rapid onset of acute liver injury in the presence of 
low grade chronic form of the disease (Khashab, Tector, & Kwo, 2007; Lee, 2003; Trey 
& Davidson, 1970).    
 In the United States (US), ALF is estimated to affect between 2000 and 2800 
people per year (Bower et al., 2007; Khashab et al., 2007; Ostapowicz et al., 2002; 
Schiodt et al., 1999). Patients admitted to the hospital with ALF typically demonstrate 
increased levels of liver enzymes in serum, the abnormal coagulation (coagulopathy 
indicated by prothrombin time (PT) greater than 15 seconds or international normalized 
ratio (INR) greater than 1.5), plus hepatic encephalopathy and without evidence of 
cirrhosis (Lee & Seremba, 2008; Ostapowicz et al., 2002; Schiodt et al., 1999).  
 There are multiple etiologies of ALF. Previously, viral hepatitis (hepatitis A, B, 
and C) was the most common cause of ALF in the US (Schiodt et al., 1999). Currently, 
acetaminophen overdose constitutes the largest single cause of ALF accounting for 46% 
of all cases. Other etiologies include drugs (11%), hepatitis B virus (7%), hepatitis A 
virus (3%), autoimmune hepatitis (5%), ischemia (4%), and Wilson’s disease (2%). 
Diseases or events, other than those listed previously, cause 7% of ALF cases and 14% of 
cases are from indeterminate causes (Lee & Seremba, 2008).  
 The etiology of ALF varies worldwide. Western countries (including Australia) 
document the majority of their ALF cases as being due to acetaminophen (paracetamol) 
toxicity. The United Kingdom reports a high prevalence of suicidal overdoses using 
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acetaminophen in the 1990s, accounting for 73% of ALF cases (Ostapowicz et al., 2002). 
That has decreased in part due to legislation to restrict sales of acetaminophen to a level 
of 57% (W. Bernal, Auzinger, Dhawan, & Wendon, 2010). In Asia and other developing 
countries, viral hepatitis (hepatitis A, B, and E) remains the leading cause of ALF. There 
is no vaccine for hepatitis E and vaccines for hepatitis A and B are less available in these 
countries. Hepatitis A and E are mainly transmitted by fecal-oral transmission routes and 
are closely associated with poor hygiene and sanitation. Hepatitis E is now the most 
common cause of ALF in India, Pakistan, China, and Southeast Asia (W. Bernal et al., 
2010). The unavailability of many of the therapeutic drugs known to cause ALF in these 
countries is another reason why viral hepatitis is the leading cause of ALF in developing 
countries (W. Bernal & Wendon, 2000; Boeker, 2001; Ostapowicz et al., 2002; Polson & 
Lee, 2007). 
 Common therapeutic (both prescription and non-prescription) drugs that have 
been documented as causing ALF include acetaminophen (as previously noted), anti-
tuberculosis, antiepileptic, and antibiotic pharmaceuticals. Antibiotics that have 
frequently been cited as causing ALF include isoniazide, sulfa-related compounds, 
quinolones, amoxicillin, and flucloxacillin.  Telithromycin (Ketek), a recently released 
antibiotic, underwent a subsequent review by the US Food and Drug Administration 
(FDA) advisory panel, which resulted in severely limited future use and a “black box 
warning”. A “black box warning” is a warning mandated by the FDA to appear on the 
full prescribing information of a prescription medication. Such a warning must be printed 
inside a box with a black outline at the top of the information sheet used by doctors and 
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pharmacists. A modified version of the same warning will appear on the patient 
information sheet. The restrictions resulted from numerous reports of ALF with short 
onset (as few as two days from initial use to symptoms of ALF), presence of abdominal 
pain, fever, and ascites (Lee & Seremba, 2008; Mindikoglu, Magder, & Regev, 2009).   
 While viral hepatitis and drug induced liver injury account for the majority of 
ALF worldwide, other etiologies are known.  Autoimmune hepatitis (AIH) is an immune-
mediated disease in which human leukocyte antigen (HLA) class II antigens are present 
on the surface of the hepatocyte and are the apparent target of the immune attack by the 
body’s immune system. The immune response is complex and may involve T-cell 
activation, adhesion between immune synapses, cytokine production, and T-cell receptor 
configuration (Heathcote, 2003). Ischemia can result from a reduction of the blood flow 
to the liver due to systemic circulatory collapse or occlusion of the hepatic vein. Systemic 
circulatory collapse may result from loss of intravascular volume (hypovolemia) due to 
blood loss or other fluid loss due to massive diarrhea, congestive heart failure, or septic 
shock. Occlusion of the hepatic artery (Budd-Chiari Syndrome) may result from 
thrombus, fibrous obliteration, or tumor invasion (DeLeve, 2003). Metabolic anomalies 
result in the disruption of pathways that are important in the synthesis or transport of 
proteins in the liver, of which Wilson’s disease (progressive accumulation of copper in 
hepatocytes) is the most common form seen in the US. Acute liver disease during 
pregnancy may also result in acute liver failure (Sokol, 2003). While there are three main 
forms of acute liver disease in pregnancy, acute fatty liver of pregnancy (AFLP) is the 
form most commonly seen in ALF. The cause of AFLP is unknown. Mild symptoms of 
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liver disease generally begin near 35 weeks gestation and may quickly progress to ALF 
and death (of mother and baby) if delivery is not initiated (Zimmermann & Christman, 
2003). 
 Spontaneous recovery from ALF occurs in less than 50% of patients. 
Approximately 40% are placed on liver transplant waiting lists, but only 25% of the 
overall ALF population, receive a liver graft. Overall, 30% of patients diagnosed with 
ALF die within 21 days of the onset of illness (Bower et al., 2007; Lee & Seremba, 
2008). Causes of death include cerebral edema, multi-organ failure, sepsis, cardiac 
arrhythmia or arrest, and respiratory failure (Ostapowicz et al., 2002).  
 Acute liver injury (ALI) is similar to ALF in that it is characterized by sudden 
severe liver cell dysfunction in patients with acute illness of less than 26 weeks duration 
(less than 2 weeks for acetaminophen etiology) but with no evidence of HE at the time of 
hospital admission. HE is diagnosed by neuropsychiatric evaluations focusing on mental 
and motor status (Ferenci et al., 2002). If HE develops, the patient’s diagnosis changes to 
ALF. At the time of hospital admission, patients with ALI, as defined by the USALFSG, 
present with increased liver enzymes, and coagulopathy (prothrombin time (PT) greater 
than 20 seconds or international normalized ratio (INR) greater than 2.0) but do not 
demonstrate any encephalopathy.  
 When ALF is described in gastroenterology textbooks (Mendler et al., 2003), 
there is no distinction between ALF and ALI, as HE is graded as 0, 1, 2, 3, or 4. All 
information describing ALF and patient demographics above are based upon the ALF 
definition that does not include the ALI patients who have a HE grade of 0. Information 
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characterizing the ALI subject population will be presented below, however, for the 
purposes of this study ALF and ALI will be distinguished only by their coma grade:  ALI 
patients have a presenting coma grade of zero and ALF patients and ALI patients who 
develop HE have coma grades of 1 – 4. Throughout the rest of this discussion, unless a 
distinction between ALF and ALI is necessary, ALF will be used to refer to both ALF 
and ALI subjects in this study. 
 The etiologies of ALI are the same as those of ALF.  While there are no figures 
available that document the number of ALI cases in the US, the USALFSG has estimates 
of the number of the various etiologies and the outcomes of ALI.  Of the 163 ALI cases 
in the USALFSG database collected prior to October 1, 2010, 23% went on to develop 
HE and were transferred to the ALF database. Ninety one percent of the ALI cases went 
on to attain transplant free survival while 7% required a liver transplant and 2% died. As 
with ALF, acetaminophen poisoning accounts for the largest percentage of ALI cases 
(60%). Autoimmune hepatitis (10%) and drug-induced liver injury (9%) account for the 
next two largest numbers of cases. Other etiologies include hepatitis B virus (5%), 
hepatitis A virus (1%), mushroom poisoning (2%), shock (<1%), hepatitis E virus (<1%), 
and acute fatty liver of pregnancy (<1%). Diseases or events other than those listed 
caused 2.5% of ALI cases and cases from indeterminate causes account for 8% of the 
cases (United States Acute Liver Failure Study Group, 2011). 
Bacterial Infection and Sepsis 
Infection is a pathologic process that is initiated when normally sterile tissue or 
fluid or a body cavity is invaded by pathogenic or potentially pathogenic microorganisms 
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(Levy et al., 2003). Common types of infections that are diagnosed and treated by 
physicians include wound infections, urinary tract infections, upper respiratory tract 
infections, pneumonia, and intestinal tract infections. All of these can range in severity 
due to the specific organism, the patient’s status (co-existing conditions, age, etc.), and 
whether or not treatment is received in a timely fashion.  
SIRS, Sepsis, Severe Sepsis, and Septic Shock 
 The 1992 American College of Chest Physicians (ACCP) and the Society of 
Critical Care Medicine (SCCM) Consensus Conference convened to “to provide a 
conceptual and practical framework to define the systemic inflammatory response to 
infection, which is a progressive injurious process that falls under the generalized term 
‘sepsis’ and includes sepsis-associated organ dysfunction as well” (Levy et al., 2003). 
Prior to this point, the terms sepsis, sepsis syndrome, and septic shock were used 
interchangeably when referring to various points on the continuum of the infection 
process (from signs and symptoms of infection to septic shock and organ dysfunction). 
The definitions for systemic inflammatory response syndrome (SIRS), sepsis, severe 
sepsis, and septic shock were developed and later reviewed and revised by the 2001 
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference sponsored 
by the SCCM, ACCP, the European Society of Intensive Care Medicine (ESICM), the 
American Thoracic Society, and the Surgical Infection Society. The revised terms are 
widely used today by physicians to make clinical decisions but are not diagnostic in 
nature. The terms only provide a means for identifying which specific criteria that 
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patients meet when they are suspected of having a systemic response to infection (Levy et 
al., 2003; Nystrom, 1998; Rangel-Frausto, 2005).   
 The term systemic inflammatory response syndrome (SIRS) was introduced to 
describe the activation of the immune response system by localized or generalized 
infection, trauma, thermal injury, or sterile inflammatory processes. SIRS can be initiated 
by both infectious and non-infectious conditions. Patients with SIRS are defined as 
having two or more of the following clinical findings:   
 Body temperature of >380C or <360C  
 Heart rate >90 beats per minute 
 Respiration rate >20 breaths per minute  
 PCO2 <32 mm Hg (normal approximately 35 – 45 mmHg)  
 White blood cell (WBC) count >12.0 x 103 cells/mm3 of blood , <4.0 x 103 
cells/mm
3 
of blood, or >10% bands (immature cells)  
However, these criteria are too non-specific to be useful in identifying a specific cause 
(infectious vs. non-infectious) for the activation of the immune response (Levy et al., 
2003). 
 Sepsis was defined by the 2001 conference as SIRS in the presence of a 
confirmed infection. Infection resulting in sepsis sets off a cascade of inflammatory 
processes that lead to activation of the coagulation system. This eventually leads to 
alterations in microvascular circulation that result in organ dysfunction. Positive 
identification of an infection can be a difficult and lengthy process. Therefore, if one or 
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more of the following conditions and SIRS are present, a presumptive diagnosis of sepsis 
can be made: 
 Significant edema or positive fluid balance (fluid intake greater than fluid output 
of 20 mL/kg over 24 hrs or more) 
 Hyperglycemia (plasma glucose >120 mg/dL) in the absence of diabetes 
 Biomarkers of acute inflammation: plasma C-reactive protein >2 SD above the 
normal value or plasma procalcitonin >2 SD above the normal value 
 Mixed venous oxygen saturation (SVO2) >70% (measured from a pulmonary 
artery, with a high value indicative of low oxygen demand resulting from such 
causes as hypothermia, anesthesia, pharmacologic paralysis, and sepsis 
 Cardiac index >3.5 L/min/M2 (normal amount of blood pumped while the body is 
“at-rest” by the ventricles per minute relative to body size is 3 L/min/M2) 
These criteria are signs of potential early organ failure that may trigger a physician to 
think that a patient “looks” septic (Edwards, 1991; Khalili et al., 2010; Levy et al., 2003; 
Mohrman & Heller, 2006). 
 Severe sepsis is defined as sepsis with organ dysfunction. Organ dysfunction, 
hypoperfusion, and hypotension variables denoting septic shock include (but are not 
limited to):   
 Arterial hypoxemia (PaO2/fraction of inspired oxygen [FiO2] ratio of <300 torr – 
normal values are >400; <300 is indicative of acute lung injury) 
 Acute oliguria (urine output <0.5 mL/kg/h for at least 2 h) 
 Creatinine >0.5mg/dL increase above baseline 
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 Coagulation abnormalities (international normalized ratio >1.5 or activated partial 
thromboplastin time >60 sec) 
 Thrombocytopenia (platelet count <100,000/mm3) 
 Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 mmol/L) 
 Hyperlactatemia (>1 mmol/L) 
 Arterial hypotension (systolic blood pressure <90 mmHg, mean arterial pressure 
(MAP) <70 mmHg (calculation based upon systolic and diastolic values; the 
average arterial blood pressure during a single cardiac cycle and normally 70 – 
110 mmHg), or a systolic blood pressure decrease >40 mmHg from baseline) 
 Altered mental status 
 
These parameters represent one level of organ dysfunction. The degree of organ 
dysfunction may be defined by using the Sequential Organ Failure Assessment (SOFA). 
SOFA is a six-organ dysfunction/failure score that measures the function of the lungs, 
coagulation, liver, heart, central nervous system, and kidneys. When using the SOFA 
system, each organ is graded on a scale of 0 – 4 depending upon the level of the 
parameter being assessed. Patients with severe sepsis exhibit a level of organ dysfunction 
that corresponds roughly with SOFA level of two for each organ system (Levy et al., 
2003; Mohrman & Heller, 2006; Nystrom, 1998).  
 Septic shock is a state of acute circulatory failure that is characterized by 
hypotension even with adequate resuscitation with fluids and is unexplained by any other 
cause. The 2001 Consensus Conference (Levy et al., 2003) defined the level of 
hypotension in septic shock using the following levels: 
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 Systolic arterial pressure < 90 mm Hg 
 Mean arterial pressure (MAP) <60 mm Hg 
 A reduction in systolic blood pressure >40 mm Hg from baseline  
 For physicians who have to identify patients with SIRS, sepsis, severe sepsis, and 
septic shock, these definitions still present difficulties since none of the criteria in the 
current definitions are specific for infection or sepsis. Physicians still resort to the clinical 
impression that “he/she looks septic” then looks for a source of infection by ordering 
various cultures and tests to identify a causative agent (Levy et al., 2003).  
 ALF has many clinical similarities to septic shock leading to the suspicion that 
they share pathogenic mechanisms that lead to the progression from SIRS to multiple 
organ dysfunction. ALF patients are prone to infection due to loss of the protective 
effects of the liver further confusing the picture:  “What is ALF without sepsis?” and 
“What is sepsis in ALF?”. Studies have shown that the presence of SIRS in ALF is 
associated with progression to hepatic encephalopathy and that the hemodynamic profile 
in ALF patients is similar to that seen in septic shock. While the systemic inflammatory 
profile is well understood in sepsis and septic shock, this is not the case in ALF 
(Antoniades et al., 2008; Rolando et al., 2000; Vaquero et al., 2003). 
 While SIRS and sepsis in ALF have not been well studied to date, ALF patients 
do have an increased risk of infection and subsequently developing sepsis and sepsis-
induced organ failure (Rolando et al., 2000; Wade et al., 2003; Stravitz, 2008). There is 
much confusion between signs and symptoms of ALF and signs and symptoms of sepsis.  
The overlap pertains to the fact that the diagnosis of sepsis requires the finding of a 
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positive blood culture, which is often delayed or not detected, even in cases where 
presumptive evidence of bacterial infection is very strong. It has been estimated that as 
many as 80% of ALF patients develop bacterial infections. The most common types of 
infections include pneumonia (50%), urosepsis (22%), IV catheter-induced bacteremia 
(12%), and spontaneous bacteremia (16%). Infection is associated with progressive 
worsening of HE, and is one of the most common causes of multi-organ dysfunction and 
death in ALF (Stravitz, 2008; Vaquero et al., 2003).  
There are multiple reasons for this susceptibility to infection. Patients with acute 
liver failure have immunological defects that include impaired function of the white 
blood cells and decreased activity of plasma proteins, including components of the 
complement cascade. ALF patients are also subject to an increased use of invasive 
procedures that are associated with increased risk of infection. Such procedures include 
insertion of intravenous lines, monitors for intracranial pressure and arterial pressure, 
urine catheters, and mechanical ventilators. Cerebral edema increases the chance of lung 
infection because chest physiotherapy and bronchial suction are contraindicated.  
Methods to Identify Bacterial Organisms 
 Diagnosis of bacterial infection by the microbiology laboratory is a time 
consuming multi-step process. The process of identifying an infection begins by choosing 
an appropriate specimen, proper collection of the specimen to avoid contamination, 
prompt transportation to the laboratory, and providing the laboratory with appropriate 
information concerning the specimen and the patient. Once the specimen is in the 
laboratory, the historical approach to identifying bacterial pathogens involved inoculating 
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the specimen onto appropriate culture medium and incubating the culture specimen for 24 
to 48 hours. If bacteria grow, isolated colonies are chosen to subculture for identification 
and antibiotic susceptibility testing, requiring an additional 24 hours. The total time 
required to identify the offending organism and determine its antimicrobial susceptibility 
profile is typically 48 to 72 hours (Levinson, 2010).  
 In some cases, additional time is required because patients have previously 
received antibiotics or the infectious organisms are slow growing. Some organisms will 
not grow using standard culture techniques, require special media or other growth 
conditions, and some bacteria do not survive the collection and transport process 
(Fenollar & Raoult, 2007; Peters, van Agtmael, Danner, Savelkoul, & Vandenbroucke-
Grauls, 2004; Schrenzel, 2007; Sixou, 2003; Stefani, 2009). Despite these drawbacks, 
culture remains the gold standard for the detection of bacteria in patients with infections.  
Cultures have the advantage because they can identify both organisms that are suspected 
and those that are unsuspected as being the cause for infections (Sixou, 2003). 
 In the past 10 to 20 years, new methods have been developed to identify bacteria 
causing infections. These methods include polymerase chain reaction (PCR), 
fluorescence in situ hybridization (FISH), DNA-based microarray, mass spectroscopy, 
and immunoassay. FISH and PCR techniques have been shown to decrease the time 
required to identify bacteria from blood culture samples (Peters et al., 2004; Stefani, 
2009). PCR has been shown in multiple studies to be able to identify bacteria directly 
from blood culture bottles (Gebert, Siegel, & Wellinghauser, 2008; Jaffe, Lane, Albury, 
& Niemeyer, 2000; Kilic, Muldrew, Tang, & Basustaoglu, 2010; Ruimy et al., 2008; 
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Stefani, 2009), from culture swabs (Francois et al., 2003), from cerebral spinal fluid (du 
Plessis, Smith, & Klugman, 1998), and from colonies already isolated in culture (du 
Plessis et al., 1998; Geha, Uhl, Gustaferro, & Persing, 1994; Georghiou et al., 1995; 
Hsueh et al., 1998; Sabet et al., 2006; Sarwari et al., 2004). Mass spectroscopy, while not 
commonly used, has been shown to identify bacteria accurately from isolates and clinical 
samples (Ho & .Reddy, 2010). Microarray techniques have been used to identify bacteria 
both from isolates (Strommenger et al., 2007) and from blood culture bottles (Tissari et 
al., 2010). Many of these technologies can identify specific bacterial species and strains 
that have known susceptibility patterns. While this does not eliminate the need for 
antimicrobial sensitivity studies, it may improve the process of identifying appropriate 
antibiotic therapy in some cases (Francois et al., 2003; Ruimy et al., 2008; Stefani, 2009; 
Strommenger et al., 2007; Tissari et al., 2010). 
 All of these methods show promise by decreasing the time required to identify 
bacteria from clinical specimens, but major drawbacks. In all cases, you can only “find 
what you are looking for” (Sixou, 2003). The probes required for the FISH, PCR, and 
microarray techniques are pre-determined. The selected probes will test for multiple 
bacterial species and strains but multiple arrays must be used to expand the range of 
organisms that can be detected. Mass spectroscopy requires either pure culture isolates or 
significant pre-treatment of samples to identify organisms in complex specimens (Ho & 
Reddy, 2010). PCR techniques are susceptible to laboratory contamination and 
background bacterial DNA from either dead organisms or from organisms that are 
present but not responsible for the infection (Stefani, 2009).      
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Procalcitonin 
 Procalcitonin is the precursor form of calcitonin, a hormone whose primary 
source is the parafollicular C cells of the thyroid gland. Calcitonin has a hypocalcemic 
and hypophosphatemic effect, inhibiting bone resorption, and stimulating the kidney to 
excrete phosphorus, calcium, and sodium. Calcitonin can be used as a biomarker of 
medullary thyroid cancer (MTC). However, the mechanisms by which calcitonin 
produces the above effects in the human body are not known. The removal of the thyroid, 
gland such as for treatment of MTC, does not cause a disruption in calcium hemostasis 
(Becker, Nylen, White, Muller, & Snider, 2004; Bracq et al., 1993; Carrol, Thomson, & 
Hart, 2002; Muller & Becker, 2001).   
 PCT is one of a group of peptides in the calcitonin super-family of peptides. Other 
peptides in the group include calcitonin gene-related peptide I, II (CGRP-I, CGRP-II), 
amylin, and andrenomedullin. The PCT peptide has an approximate molecular weight of 
14.5 kDa and consists of a sequence of 116 amino acids. Both PCT and CGRP-I are 
encoded by the Calc-1 gene located on chromosome 11p15.4 (Christ-Crain & Muller, 
2008; Jin & Khan, 2010; Russwurm, Oberhoffer, Zipfelk, & Reinhart, 1999). The peptide 
has three regions (Figure 1): the PCT amino terminus, the mature calcitonin segment, and 
the carboxyl-terminus called katacalcin (Carrol et al., 2002). 
 
Figure 1:  Schematic of Procalcitonin Molecule 
Figure was derived from E.D. Carrol et al., (2002) International Journal of Antimicrobial Agents, 20: 1-9.  
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In the absence of infection, the production of PCT outside of the neuroendocrine 
cells of the thyroid and the lung is suppressed. In the presence of sepsis, all tissues 
produce PCT. Because of this dual role, PCT is considered a “homokine”.  Homokines 
can either act as a hormone as in the normal physiologic state or as a cytokine during 
inflammatory processes (Muller & Becker, 2001; "PCT in patients with sepsis", n.d.). To 
date no other causes of PCT increase has been determined.  
        The factors mediating the production of homokines are as yet unknown. It may be 
induced either by toxins produced by bacteria or by humoral- or cell-mediated host 
response. As with other cytokines, there is little intracellular storage of PCT during 
sepsis. While synthesis of PCT is necessary for the production of calcitonin, animal 
studies have shown that increased concentrations of PCT may have lethal effects during 
sepsis. Administration of PCT to septic hamsters with peritonitis doubled the death rate to 
over 90%. Immunoneutralization of PCT by the administration of antiserum in septic 
hamster and pig studies led to increased survival of these animals (Muller & Becker, 
2001; Nylen et al., 1998; Nystrom, 1998; Whang et al., 1999). 
 Procalcitonin Testing 
 Most PCT assays have been developed in cooperation with BRAHMS Diagnostic 
GmbH. BRAHMS placed the first PCT assay into use in 1996, with a rapid test following 
in 1999. The FDA approved the use of the manual BRAHMS PCT LIA (formerly 
LUMItest PCT) in the US in 2005. The BRAHMS PCT LIA, (“Immunoluminometric 
assay (ILMA) for the determination of PCT”, 2005) is a dual monoclonal antibody 
luminescence immunoassay. The assay uses a coated tube technique in which the anti-
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calcitonin capture antibody is immobilized on the inner surface of the tube and a second 
anti-calcitonin antibody is labeled with a luminescent acridine derivative. During the 
incubation phases of the procedure, PCT is “sandwiched” between the two calcitonin 
antibodies. The amount of PCT in the sample is determined by measuring the 
luminescence signal using a luminometer when Basiskit LIA reagents are added to the 
tube. The intensity of the luminescence signal (RLUs, relative light units) is directly 
proportional to the PCT concentration. The assay takes two to three hours to complete, 
requires standards and controls to be analyzed with each run, and is usually performed in 
batch mode ("Immunoluminometric assay (ILMA) for the determination of PCT (coated 
tube system)", 2005; McGee & Baumann, 2009; Steinbach et al., 2004). 
 The first automated PCT assay was the BRAHMS KRYPTOR assay. The 
KRYPTOR assay received FDA clearance for use in the US in March 2008. This assay 
uses Time Resolved Amplified Cryptate Emission (TRACE) technology, with a non-
radiative transfer of energy. The PCT molecule is sandwiched between a PCT antibody 
tagged with europium cryptate (donor) and a PCT antibody tagged with XL665 
(acceptor) forming an immune complex. When a pulsed nitrogen laser at 337 nm excites 
the sample, the donor emits a fluorescent signal at 620 nm with an excited state t1/2 in the 
milli-second range. The acceptor emits a fluorescent signal at 665 nm with an excited 
state half-life (t1/2) in the nano-second range. If the donor and acceptor are bound in an 
immune complex, the fluorescent signal of the acceptor is amplified, and its t1/2 is 
prolonged to the microsecond range by resonance energy transfer from the donor. The 
signal intensity at 665 nm is proportional to the amount of PCT in the sample. The assay 
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calibration is good for seven days and results are available in 25 – 40 minutes 
("BRAHMS PCT sensitive KRYPTOR", 2008; McGee & Baumann, 2009; Steinbach et 
al., 2004). 
 The LIA (LUMItest) and the Kryptor assays have been utilized for most of the 
clinical studies examining the clinical utility of measuring PCT to date. A multi-center 
study compared the two assays for assay characteristics including within- and between-
run estimates of precision, linearity, functional assay sensitivity, and a comparison of 
PCT values on patients’ samples. The study found that the main differences between the 
assays were that the LUMItest, being a manual assay, required more time to obtain 
results. Furthermore, the functional sensitivity of the LUMItest was higher (0.30 ng/mL, 
although some studies have shown it to be as low as 0.1 ng/mL) than that of the 
KRYPTOR assay (0.04 ng/mL). The functional assay sensitivity is the lowest 
concentration of PCT that can be analyzed with a coefficient of variation (CV) less than 
or equal to 20%. The reference range for the two assays differs due to the functional 
sensitivities. The reference range for normal (non-infected) subjects is <0.3 ng/mL for the 
LUMItest assay and <0.05 ng/mL for the KRYPTOR assay. The analytical measurement 
range for the KRYPTOR assay extends only to 50 ng/mL, while the LUMItest assay can 
measure PCT concentrations up to 500 ng/mL. However, the instrumentation for the 
KRYPTOR assay has automatic dilution protocols that increase the measurement range 
up to 5000 ng/mL. The within-run and between-run precision of the KRYPTOR assay 
was superior to the LUMItest assay.  Within-run precision CVs were 3.14% - 4.56% (at 
concentrations of 18.3 ng/mL and 0.26 ng/mL, respectively) for KRYPTOR vs. 3.14% – 
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6.83% (at concentrations of 1.69 ng/mL and 15.70 ng/mL, respectively) for LUMItest 
and between-run was 5.09% - 8.34% (at concentrations of 3.40 ng/mL and 9.18 ng/mL, 
respectively) for the KRYPTOR and 6.28% - 16.44%, (at concentrations of 15.77 ng/mL 
and 0.32 ng/mL, respectively) for the LUMItest. The highest correlation between the 
LUMItest and the KRYPTOR assays was in the 0 – 50 ng/mL range, which is the 
common measurement range for both assays with undiluted specimens. Linear regression 
analysis on PCT results obtained on patients’ samples demonstrated r = 0.92 in the 0.3 – 
50 ng/mL range (n = 534) and r = 0.91 for all data (n = 696). The conclusion was that 
there should be no clinically relevant difference between PCT values obtained by the two 
assays (Steinbach et al., 2004).  
Siemens Healthcare Diagnostics has developed the BRAHMS PCT assay for their 
ADVIA Centaur Immunoassay Analyzer. The assay has not yet been approved for use in 
the US by the FDA but has been approved by the European Union (EU) regulatory 
agency for use in Europe, Australia, and Canada. The assay is a one-pass antibody 
sandwich immunoassay that uses an anti-fluorescein isothiocyanate-labeled ((FITC) 
monoclonal antibody covalently bound to paramagnetic particles (PMP), two fluorescent 
capture monoclonal antibodies, and an acridinium ester (AE)-labeled monoclonal 
antibody. The PCT molecule is sandwiched between fluorscein labeled antibodies and 
acridinium ester labeled antibodies with the whole complex held to an anti-fluorscein 
labeled paramagnetic particle (solid phase structure). When the acridinium labeled 
complex is exposed to acid and then base reagents a chemiluminescent reaction occurs 
which produces a flash of light that is measured in RLUs. The RLUs are directly 
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proportional to the amount of PCT in the serum ("Advia centaur immunoassay system 
reference manual", 2003; "Advia centaur and advia centaur XP systems - procalcitonin 
(PCT)", 2010).  
 The ADVIA Centaur BRAHMS PCT (CenPCT) has been compared to the 
BRAHMS KRYPTOR assay in a 600 patient study in which single replicate serum 
samples were assayed using each method. The specimen concentration ranged from 0.01 
ng/mL to 573 ng/mL. Regression analysis of the results produces a correlation coefficient 
(r) of 0.993 and a slope of 1.00 and an intercept of -0.04. Further studies produced a 
functional assay sensitivity of <0.05 ng/mL. A normal population study resulted in an 
average PCT value of 0.02 ng/mL (Per package insert the normal range is reported as 
<0.1 ng/mL.). The analytical range of the CenPCT is 0.02 – 75.0 ng/mL. The ADVIA 
Centaur has an automatic dilution protocol that allows for an increase in the measurement 
range of up to 1440 ng/mL. The within-run precision CVs for the CenPCT were 1.1% - 
6.1% (at concentrations of 33.77 ng/mL and 0.06 ng/mL, respectively). The between-run 
precision CVs for the CenPCT were 3.3% - 8.6% (at concentrations of 33.77 ng/mL and 
0.06 ng/mL, respectively) (Aso, Baker, Freeman, & Navarro, 2009). Table 1 shows a 
summary of the BRAHMS KRYPTOR and ADVIA BRAHMS PCT assays. 
PCT as a Biomarker of Bacterial Infection or Sepsis 
 Assciot. Gendrel, Carson, Raymond, Guilbaud, and Bohuon (1993) first suggested 
procalcitonin could be a marker of bacterial infection in 1993 when they found increased 
concentrations of PCT in pediatric patients with bacterial infection (Bohuon, 2000; Carrol 
et al., 2002) . In a subsequent study by Dandonna in 1994, healthy volunteers received a  
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Table 1:  KRYPTOR vs. ADVIA Centaur Assays for SPCTC 
 BRAHMS KRYPTOR PCT ADVIA Centaur BRAHMS PCT 
Functional sensitivity 0.04 ng/mL <0.05 ng/mL 
Normal population <0.05 ng/mL 0.02 ng/mL 
Reference range <0.05 ng/mL <0.1 ng/mL 
Analytical range 0.05 – 50 ng/mL 0.02 – 75 ng/mL 
Range with auto-dilution 5000 ng/mL 1440 ng/mL 
Within run CVs 3.14% - 4.56% 1.1% - 6.1% 
Between run CVs 5.09% - 8.34% 3.6% - 8.6% 
 
bolus of endotoxins after which SPCTCs were measured at defined intervals. PCT 
concentrations had started to rise by three hours, reached a plateau by six hours, and 
remained at these levels for up to 24 hours (Bohuon, 2000; Carrol et al., 2002). 
 In a case report of a 76 year old female who received an intravenous (IV) solution 
contaminated (probably resulting from improper storage of the IV solution between dose 
administrations) with Acinetobacter baumanii, PCT rapidly increased in the blood 
following development of systemic infection (Brunkhorst, 1998). The PCT was 
undetectable at 1.5 hours after the injection, became detectable at 2.5 hours, and peaked 
at 13.5 hours. Serial measurements of PCT during follow-up days determined that the 
PCT half-life is 22.5 hours (Brunkhorst, Heinz, & Forycki, 1998).  
 In a study in which seven healthy volunteers were administered intravenous 
solutions containing endotoxins from Escherichia coli 0113:H10:k, PCT was not 
detectable at two hours post injection but was detectable in all samples at 4 hours. Values 
peaked between 8 - 12 hours post injection and remained high at 24 hours (Dandona et 
al., 1998). 
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  Studies examining the elimination rate of PCT indicate that the approximate half-
life of PCT is 30 hours for patients with normal renal function. The median PCT half-life 
in patients with renal dysfunction was 33.1 – 44.7 hours. While patients with renal 
dysfunction may have a longer PCT half-life, the kidneys do not appear to be the major 
pathway of PCT elimination from the blood (Meisner, Schmidt, Huttner, & 
Tschaikowsky, 2000; Meisner, Huettemann, Schmidt, Hueller, & Reinhart, 2001). These 
results would suggest that PCT can be used to identify bacterial-induced systemic 
inflammation. 
 Studies to demonstrate the clinical utility of PCT as a biomarker of bacterial 
infection have taken two approaches: 1) use of PCT as a diagnostic biomarker of 
infection and 2) use of PCT to confirm the appropriateness of specific antibiotic therapy 
and patient outcomes.  Studies of PCT as a diagnostic biomarker of infection have looked 
at patients with respiratory tract infections, peritonitis, meningitis, and post-surgical 
infections in the setting of the emergency department (ED), intensive care unit (ICU), and 
general hospital wards. There have been at least nine randomized trials (seven single-
center and two multi-center) looking specifically at the use of PCT to guide antibiotic 
therapy.   
 Several investigators have examined the utility of measuring PCT in patients that 
present to the ED, ICU, and general hospital wards with signs of infection or sepsis. In 
two studies, subjects were admitted to the ICUs for their respective hospitals with a 
suspected diagnosis of infection. The studies classified the subjects based upon their 
SIRS status into one of four groups: SIRS, sepsis, severe sepsis, or septic shock. In a 
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study by Brunkhorst, Wegscheider, Forycki, & Brunkhorst (2000), a PCT cutoff of 2.0 
ng/mL predicted severe sepsis with an estimated 96% sensitivity and 86% specificity 
using receiver operator curve (ROC) analysis. A cutoff of 11.6 ng/mL predicted septic 
shock with an estimated 53% sensitivity and 72% specificity. Mean PCT values for the 
groups were 0.41 ng/mL (SIRS), 0.53 ng/mL (sepsis), 6.91 ng/mL (severe sepsis), and 
12.89 ng/mL (septic shock). A study by Harbarth, et al. (2001) had similar results. 
Investigators determined that a PCT cutoff of 1.1 ng/mL predicted sepsis with 97% 
sensitivity and 78% specificity using ROC analysis. The mean PCT values for the groups 
were 0.6 ng/mL (SIRS), 3.5 ng/mL (sepsis), 6.2 ng/mL (severe sepsis), and 21.3 ng/mL 
(septic shock).  
 Cheval, C., Timsit, J. F., Garrouste-Orgeas, M., Assicot, M., De Jonghe, B., 
Misset, B., et al. (2000) evaluated the use of PCT to assess infection in the 
medical/surgical ICU setting. The study included four groups of acutely ill patients 
admitted to the ICU. Sixty patients were assigned to one of four groups: 1) shock (with 
bacterial infection), 2) non-septic shock (with no bacterial infection), 3) infected, and 4) 
control (no evidence of infection). Patients with proven bacterial infection (groups 1 – 3) 
had mean PCT concentrations of 72 ng/mL which was significantly higher than the PCT 
results for patients in the control group (Group 4) at 2.9 ng/mL (p-value = 0.0003). 
Patients with shock and a confirmed bacterial infection (Group 1) had higher mean PCT 
values than those with shock and no confirmed infection (Group 2), 89 ng/mL and 2.9 
ng/mL, respectively (p-value = 0.0004). A SPCTC of at least 20 ng/mL predicted positive 
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blood cultures in infected patients with sensitivity of 89 + 21% and specificity of 83 + 
15%.      
 A study by Guven, H., Altintiop, L., Baydin, A., Esen, S., Aygun, D., Hokelek, 
M., et al. (2002) enrolled 34 patients that were admitted to the ED between January 1999 
and September 2000, who were at risk for sepsis due to hospitalization or insertion of 
intravascular and/or urinary catheters. All patients met at least two criteria for SIRS. The 
patients were divided into two groups:  sepsis not suspected and sepsis suspected. The 
sepsis not suspected group included 15 patients who had minor infections (upper 
respiratory tract, otitis media, or gastroenteritis) who were observed in the ED for 24 
hours and then discharged. The sepsis suspected group included 19 patients with a history 
of previous cerebrovascular disease, chronic obstructive pulmonary disease, diabetes 
mellitus, or previous hospitalizations but had no documented bacterial infection. The 
patients in the sepsis not suspected group all had negative blood cultures and an average 
SPCTC of 0.23 ng/mL. In the sepsis suspected group, 13 of 19 patients had positive 
blood cultures and an average PCT value of 67.89 ng/mL. Two patients with negative 
blood cultures had near normal PCT values (normal 0 – 5 ng/mL) while two others had 
extremely high values (approximately 500 ng/mL) and were diagnosed with acute 
pancreatitis (Guven et al., 2002). 
 In a study by Brunkhorst, Eberhard, & Brukhorst (1999), 27 patients with adult 
respiratory distress syndrome (ARDS) were prospectively studied to determine the ability 
of PCT to discriminate between septic and non-septic causes of ARDS: 10 patients 
developed ARDS due to injuries to the lung and 17 developed ARDS due to bacterial 
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infection. Serum PCT concentrations were measured every four to six hours for 72 hours 
immediately following a diagnosis of ARDS. PCT values in patients with non-septic 
ARDS averaged approximately 1.0 ng/mL (with no values higher than 2.9 ng/mL), while 
the PCT values in septic ARDS patients were all greater than 5.0 ng/mL (Brunkhorst et 
al., 1999).  
 In a study by Luyt, C., Guerin, V., Combes, A., Trouillet, J., Ayed, S. B., Bernard, 
M., et al. (2005), 63 prospectively enrolled patients with ventilator-associated pneumonia 
(VAP) were studied to determine if PCT kinetics could serve as a prognostic marker of 
infection in these patients. In the study, 38 patients had unfavorable outcomes (death, 
VAP recurrence, or extrapulmonary infection requiring antibiotics before Day 28) and 25 
patients had favorable outcomes (not meeting one of the unfavorable outcome 
requirements). Median PCT values were significantly higher for unfavorable outcome 
group than for the favorable outcome group on days 1, 3, and 7. On Day 1, a PCT value 
>1.0 ng/mL had an odds ratio of 12.3 of being associated with an unfavorable outcome. 
Later time points demonstrated increasing odds ratios with an odds ratio of 24.6 on day 3 
for a PCT > 1.5 ng/mL and 64.2 on day 7 for a PCT > 0.5 ng/mL (Luyt et al., 2005).   
 Reith, Mittelkotter, Wagner, & Thiede (2000) assessed serum PCT as a measure 
of the severity in patients with septic abdominal illnesses. In this prospective study, serial 
measurements of PCT were carried out in 246 patients with infective or septic episodes 
and in 66 patients with elective operations who served as controls. The causes of 
infective peritonitis in this study included pancreatitis, colon perforation, abscess, trauma, 
and mesenteric infarction. In the peritonitis group, 59 of the 246 patients died. The mean 
34 
 
 
 
PCT value in patients who died rose from 4.2 ng/mL initially, to 13.2 ng/mL at time of 
death. The remaining peritonitis subjects had a mean initial PCT value of 2.1 ng/mL that 
rose to 4.8 ng/mL on day 4 then decreased to 0.4 ng/mL at end point (day 10 post-
operatively, 3 months post-operatively for patients with metastasis, or death). PCT values 
for the control group who had no signs of post-operative infection or sepsis were within 
the reference range (0.1 – 0.8 ng/mL) for 98% of the samples tested (424 of 431 
samples). The remaining seven samples had values between 0.8 and 1.2 ng/mL. The 
results of this study indicated that PCT was elevated in septic patients with peritonitis and 
that a reduction of PCT during their clinical course was predictive of survival (Reith et 
al., 2000).  
 PCT has been shown to be a strong predictor for distinguishing bacterial and non-
bacterial meningitis (such as viral, fungal, drug related, and tick-borne disease related). In 
a study by Dubos, et al. (2008), data from 198 children admitted to six pediatric ED or 
ICU units in five European countries were retrospectively examined to determine the 
usefulness of PCT as a marker of bacterial meningitis. At a 0.5 ng/mL threshold, PCT 
had 99% sensitivity and 83% specificity for distinguishing between bacterial and aseptic 
meningitis. Ninety-six of the 198 patients studied had bacterial meningitis confirmed by a 
positive culture but only 75% had a positive gram stain report. The bacterial organisms 
identified in these patients included Neisseria meningitides, Streptococcus pneumoniae, 
H influenzae, and Streptococcus pneumoniae. The median PCT value in patients with 
bacterial meningitis was 21.5 ng/mL while the median PCT value in patients with non-
bacterial meningitis was 0.3 ng/mL (p-value < 1 x 10
-6
) (Dubos et al., 2008).  
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 In two studies of post-operative patients, PCT was examined as a biomarker of 
infection post surgery. Falcoz, P.-E., Laluc, F., Toubin, M.-M., Puyraveau, M., Clement, 
F., Mercier, M., et al. (2005) studied patients after thoracic surgery and found a mean 
PCT value in 132 non-infected patients of 0.63 ng/mL versus 3.6 ng/mL for 25 patients 
who developed a post-operative infection (p-value = 0.0001). Meisner, Tschaikowsky, 
Hutzler, Schick, & Schuttler (1998) studied 130 patients with different types of surgeries, 
measuring PCT pre-operatively and for five days post-operatively. Patients were assigned 
to one of five groups based upon the type of surgery performed: 1) minor surgery - hip 
replacement, peripheral vascular surgery, and general surgery, 2) minor abdominal 
surgery - cholecystectomy, 3) abdominal surgery of the intestine - resection of the colon, 
sigma, and rectum, and gastrectomy, 4) major abdominal or thoracic surgery -
esophagectomy, Whipple procedure, and major vascular surgery, and 5) cardiac and 
thoracic surgery - coronary artery bypass, resection of the lung, and diagnostic 
thoracotomy. For patients with a normal post-operative course without infection or sepsis 
(n = 117), the median PCT values for all groups were < 1.0 ng/mL except the surgery of 
the intestine (group three) that had a median value of 1.5 ng/mL for patients with a 
normal post-operative course without infection or sepsis. Thirteen patients (a 
heterogeneous mix of the abdominal surgery of the intestine, major abdominal or 
thoracic, and cardiac and thoracic surgery groups) had abnormal post-operative courses. 
An abnormal post-operative course was defined as fulfilling SIRS or sepsis criteria, any 
clinical sign of infection, increased body temperature above 38
0
C after post-op day 2, 
extubation after post-op day 1, requiring catecholamine therapy, cardiac insufficiency, 
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pulmonary infiltrates, local wound infection, or reoperation. This group had a median 
PCT value of 6.48 ng/mL while only one patient had an identified bacterial infection 
(Meisner et al., 1998). Both studies showed a general increase in PCT immediately 
following surgery. The amount of increase observed was dependent upon the type of 
surgery performed. However, in both studies, the PCT level was lower in patients who 
did not develop an infection or sepsis post-operatively. The cause of the higher PCT 
values in the non-septic patients (from both studies) is not entirely understood. Both 
authors noted these increases and speculated that they may be a result of the type of 
surgery (the majority of the surgeries in these patients were cardiac and thoracic in 
nature) and due to lung involvement. An increase in PCT after lung injury in the absence 
of infection has been noted (Falcoz et al., 2005; Meisner et al., 1998). 
 The above studies indicated that PCT is a good predictor of bacterial infection or 
sepsis in most cases. The studies also showed that PCT was not an absolute indicator of 
infection and should be used in conjunction with other infection indicators.  
PCT Use to Guide Antibiotic Therapy 
 Not only is serum PCT concentration measurement being used as an indicator of 
infection, but it is also being used to guide antibiotic treatment. Studies have shown that 
PCT-guided therapy has substantially reduced the amount of antibiotic used by 
decreasing the prophylactic use of antibiotics when a bacterial infection is suspected but 
not actually present and shortening the length of antibiotic treatment in bacterial 
infections that respond to therapy. The reduced number of antibiotic treatment days lead 
to fewer antibiotic adverse effects without increasing the number of adverse events 
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(Bouadma et al., 2010; P. E. Charles et al., 2009; Christ-Crain et al., 2004; Schuetz, 
Christ-Crain, & Muller, 2009; Tang, Huang, Jing, Shen, & Cui, 2009).  
 Studies have compared standard of care (SOC) antibiotic therapy to PCT guided 
antibiotic therapy in patients with lower respiratory tract infections (LRTI). Diagnoses 
that are related to LRTI include acute bronchitis, acute exacerbations of chronic 
pulmonary disease, asthma, and pneumonia. Patients presenting with signs and symptoms 
of LRTI are often treated with antibiotics, without clear evidence of a bacterial infection. 
LRTIs are mainly viral in nature. LRTI is the leading cause for antibiotic prescriptions in 
the Western hemisphere and contributes to increasing bacterial resistance to antibiotics 
(Christ-Crain et al., 2004; Schuetz et al., 2009; Schuetz et al., 2009; Schuetz, Christ-
Crain, & Muller, 2009).  
 Christ-Crain, et al. (2004) conducted a prospective randomized controlled single 
blinded intervention trial with 243 subjects enrolled in the study. The subjects were 
randomly assigned to either the SOC (standard antimicrobial therapy) or PCT guided 
groups. In the PCT group, the physician first had to declare his/her intention to prescribe 
antibiotics after which they were advised to follow the PCT algorithm for prescribing 
antibiotics. The algorithm using the serum PCT concentration was: 
 0.1 ng/mL or less indicates absence of bacterial infection and antibiotics are 
strongly discouraged  
 0.1 – 0.25 ng/mL indicates bacterial infection is unlikely and antibiotics are 
discouraged  
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 0.25 – 0.5 ng/mL indicate possible bacterial infection and the doctor is advised to 
initiate antibiotic therapy 
 0.5 ng/mL or greater is suggestive of a bacterial infection and antibiotic treatment 
is strongly suggested. 
For patients on antibiotics at the time of hospital admission, discontinuation of antibiotic 
therapy was recommended if the PCT value was less than 0.25 ng/mL (Christ-Crain et 
al., 2004). 
 The second study is the Procalcitonin Guided Antibiotic Therapy and 
Hospitalization in Patients with Lower Respiratory Tract Infections: The ProHOSP 
Study. This was an investigator initiated multi-center randomized controlled trial with 
six participating tertiary care hospitals in Switzerland. Patients were randomized into 
PCT-guided treatment group using the PCT cut-off ranges described above or SOC 
treatment to initiate or stop antibiotic treatment (Schuetz et al., 2009).  
 Both studies found that the duration of antibiotic therapy was significantly less in 
the PCT-guided antibiotic therapy groups compared to the SOC groups (Table 2) with no 
difference in the rate of adverse outcomes (death). The ProHOSP study also determined 
that the PCT-guided treatment group had fewer adverse effects (including nausea, 
diarrhea, and rash) from antibiotics than SOC (133 vs. 193 respectively), a decrease of 
28.2% (Christ-Crain et al., 2004; Schuetz et al., 2009). 
The Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients 
(PRORATA) trial was a prospective parallel group study undertaken in France to assess 
critically ill patients with suspected bacterial infections. The study was a multi-center  
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Table 2: Published Studies of PCT Guided Antibiotic Therapy vs. SOC 
  
study of patients in the medical and surgical ICUs of five university-affiliated hospitals 
and one general hospital. All adults with suspected bacterial infections in the ICUs were 
eligible for the study if they had not been receiving antibiotics before the study. Patients 
were randomly assigned to either a PCT-guided antibiotic therapy group or a SOC group. 
The results of this study (see Table 1) were similar to the previously described studies in 
that the PCT-guided therapy group - shorter average number of days of antibiotic 
exposure without affecting the rate of adverse outcomes (Bouadma et al., 2010). Table 1 
summarizes the results from the three aforementioned studies. 
 In an observational study by Charles et al., (2009) of 180 patients in France, PCT 
was monitored over four days, as part of the patients’ standard of care and the change in 
PCT values were related to appropriateness of antibiotic therapy. Patients in the ICU who 
had bacteremia, community-acquired pneumonia, or ventilator-associated pneumonia 
Antibiotic Treatment Group 
  SOC PCT guided 
Percent 
difference 
Christ-Crain      
# patients 119 124  
Mean days antibiotic treatment 12.8 10.9 -14.8% 
Died 4 4 0% 
     
ProHOSP    
# patients 688 671  
Mean days antibiotic treatment 8.7 5.7 -34.8% 
Died 33 34 3.0% 
    
PRORATA    
# patients 314 307  
Mean days antibiotic treatment 9.9 6.1 -38.4% 
Died 64 65 1.6% 
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were prospectively enrolled in the study. The appropriateness of antibiotic therapy was 
determined by retrospective chart review to obtain antimicrobial susceptibility testing 
reports by an infectious disease expert who was blinded to the PCT values and patient 
outcomes. PCT values were also obtained from the retrospective chart review. The 
authors concluded that appropriate antibiotic therapy (the isolated pathogen(s) was (were) 
susceptible to at least one drug administered at the onset of sepsis according to the 
corresponding susceptibility testing report) was associated with a greater decrease in PCT 
values in the first 48 hours of antibiotic treatment (Table 3). The patient group that had 
appropriate antibiotic therapy had a greater decrease in mean PCT values between days 
two and three, -3.9 ng/mL, than the inappropriate antibiotic therapy group, +5.0 ng/mL (p 
<0.01). The study also found that there was a greater rise in mean PCT values between 
days one and two for the inappropriate antibiotic therapy group, +5.2 ng/mL than for the 
appropriate antibiotic  group, +1.7 ng/mL (p = 0.20). They noted, however, that their 
study was a single center study and that a prospective study would be needed to assess 
PCT and clinical findings as an indicator of the effectiveness of antibiotic therapy and the 
use of more effective therapies (Charles, 2009).  
Table 3:  Comparison of SPCTC Values in Appropriate and Inappropriate Antibiotic 
Therapy 
 
 
Antibiotic Therapy 
p-value Appropriate  Inappropriate  
Number of subjects 135 45  
Average Day 1 PCT [ng/mL] 27.2 29.6 0.92 
Average Day 2 PCT [ng/mL] 27.4 40.9 0.09 
Average Day 3 PCT [ng/mL] 24.4 34.4 0.12 
Average Day 4 PCT [ng/mL] 17.3 32.4 0.03 
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 Overall these studies and others (Bouadma et al., 2010; Tang et al., 2009)  
indicate that PCT can be used to decide if antibiotic therapy is required in the case of 
suspected bacterial infection. PCT may be useful in determining if antibiotic therapy is 
appropriate prior to the availability of antimicrobial susceptibility results. 
Procalcitonin and Liver Disease 
 Initiation of antibiotic therapy as soon as possible is critical in all cases of 
bacterial infection and sepsis. However, in the ALF/ALI population this can be a double-
edged sword. Many commonly used antibiotics are known to be metabolized by the liver. 
Examples include but are not limited to sulfa-related compounds, quinolones, 
amoxicillin, and flucloxacillin. Giving a drug that is metabolized by the liver to a patient 
with liver dysfunction can lead to drug toxicity. Some cases of ALF/ALI are caused by 
use of antibiotics. The reasons that antibiotics are associated with liver injury are not 
entirely understood (Murray, Hadzic, Wirth, Bassett, & Kelly, 2008). Therefore, giving 
antibiotics to this population of patients is not always the best course of action. A clear 
indication of need is of extreme importance in this situation. Therefore, a method of 
determining the need for antibiotic use that is faster than the standard culture methods is a 
worthwhile goal. Procalcitonin could prove to be highly useful for this group of patients, 
to either identify or exclude bacterial sepsis. 
 There are few published studies on the measurement of serum procalcitonin in 
patients with liver disease, and none specifically in patients with ALF or ALI. Previously 
published studies included populations with cirrhosis (Bota, Van Nuffelen, Zakariah, & 
Vincent, 2005; Connert, Stremmel, & Eising, 2003; Spahr, Morard, Hadengue, Vadas, & 
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Pugin, 2001; Viallon et al., 2000), liver metastasis of non-liver primary solid tumors 
(Matzaraki et al., 2007), and acute and chronic liver disease (Elefsiniotis, Skounakis et 
al., 2006). The results of the cirrhosis studies present some conflicting data. Viallon et al. 
(2000) enrolled 61 subjects:  21 with spontaneous bacterial peritonitis (SBP) and 40 with 
sterile ascitic fluid (SAF). The severity of liver disease was similar in both groups with 
the SBP patients having a mean Child-Pugh score of 11 and the SAF group having a 
Child-Pugh score of 10. The Child-Pugh score is a standard measure of the severity of 
chronic liver disease based on a three point evaluation of five features of cirrhosis: the 
presence/severity of ascites and encephalopathy and the concentrations of albumin, 
bilirubin, and INR. The maximum score is 15. The median PCT values from samples 
taken at study admission prior to initiation of antimicrobial therapy were significantly 
different between the two groups, with patients in the SBP group having a mean serum 
PCT = 10.10 ng/mL while that of patients in the SAF group was 0.09 ng/mL (p-value = 
0.0001) (Viallon et al., 2000). The serum PCT measurements appear to be a marker of 
bacterial peritonitis in patients with liver disease. 
 Connert et al. (2003) enrolled 127 patients with cirrhosis. The subjects were 
divided into three groups based upon bacteriological and clinical findings. Group I had 36 
patients with decompensated liver disease (ascites, encephalopathy, variceal hemorrhages 
are the classic features evidencing decompensation) with an infection. Group II had 64 
patients with decompensated liver disease without an infection. Group III had 27 patients 
with non-decompensated liver disease and without infection. The mean PCT values for 
Groups II and III were lower (0.6 ng/mL and 0.4 ng/mL, respectively) than for Group I 
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(2.8 ng/mL) (Connert et al., 2003). Thus, serum PCT measurements appear to be a 
marker of infection in patients with cirrhosis. 
 Bota et al. (2005) studied 864 critically ill patients in the ICU, of which 79 were 
patients with cirrhosis. The cirrhotic patients were divided into three groups based upon 
severity of liver disease as measured by the Child-Pugh score. Table 4 illustrates that the 
serum PCT concentrations did not appear to vary with the severity of liver disease. The 
study did show a difference between infected and non-infected patient PCT values. Initial 
mean PCT values were approximately 1.25 ng/mL in infected cirrhotic patients, 2.0 
ng/mL in infected non-cirrhotic patients, 0.5 ng/mL in non-infected cirrhotic, and 0.4 
ng/mL in non-infected non-cirrhotic patients, but there were no significant differences in 
the PCT levels in relation to the severity of cirrhosis (Bota et al., 2005).  
Table 4:  SPCTC and Child-Pugh Score in Patients with Cirrhosis, With and Without 
Infection 
 
 Controls Patients with Cirrhosis 
All Inf NI Inf NI Inf NI 
# subjects 785 79 15 14 10 13 13 14 
Child-Pugh score   5 - 6 7 - 9 10 - 15 
SPCTC [ng/mL] – initial 0.632 0.682 1.2 0.3 1.3 0.4 1.1 0.4 
Inf = Infection; NI = No Infection 
 
 Spahr et al. (2001) measured serum PCT concentrations in 10 patients with 
cirrhosis and spontaneous bacterial peritonitis and in 10 patients with cirrhosis but 
without spontaneous bacterial peritonitis. The mean PCT values for 10 patients with SBP 
were 0.74 ng/mL vs. 0.2 ng/mL for 10 non-infected patients. The authors concluded that 
PCT was not a good indicator of infection in this group of patients possibly because the 
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absence of SIRS in the patients with SBP (Spahr et al., 2001). Therefore, serum PCT 
measurements may not be a marker of infection in patients with liver disease, if the 
infection is localized and the patient has not yet progressed to sepsis.  
 Matazaraki et al. (2007) studied the serum PCT concentrations in patients who 
had solid tumors that had metastasized to the liver. This study included 15 healthy control 
subjects (Group A), 21 patients with solid tumors that had not metastasized (Group B), 11 
patients with liver metastasis (Group C), and 11 patients with generalized metastasis 
(Group D). The PCT values were 0.284 ng/mL for Group A, 0.327 ng/mL for Group B, 
0.690 ng/mL for Group C, and 1.030 ng/mL for Group D. Table 5 shows the comparisons 
between the groups. PCT concentrations appear to increase with increasing degree of 
metastasis to levels that are similar to those found in patients with confirmed infection or 
sepsis. Further study will be required to determine if PCT can be used as a marker for 
sepsis and possibly as a marker of disease progression in this population of patients 
(Matzaraki et al., 2007). 
Table 5: SPCTC in Patients with Liver Cancer 
 Mean PCT   
(ng/mL) 
Comparison to 
Group C p-value 
Comparison to 
Group D p-value 
Group A (control) 0.284 0.10 <0.001 
Group B (solid tumor) 0.327 0.117 0.004 
Group C (liver metastasis) 0.690  0.199 
Group D (general metastasis) 1.030   
 
 Elefsiniotis, Skounakis, et al. (2006) evaluated the differences in serum PCT 
concentrations between patients with acute and chronic liver disease. PCT was measured 
in 106 consecutively hospitalized patients with liver disease at the time of admission. The 
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etiology of liver disease included alcoholic hepatitis (Group A, n = 15), alcoholic 
cirrhosis without hepatitis or bacterial infection (Group B, n = 20), decompensated 
cirrhosis with proven bacterial infection (Group C, n = 16), uncomplicated viral hepatitis-
cirrhosis (Group D, n = 42), and acute icteric viral hepatitis (Group E, n = 13). The mean 
SPCTCs were 0.40 ng/mL in Group A, 0.23 ng/mL in Group B, 9.80 ng/mL in Group C, 
0.21 ng/mL in Group D, and 0.37 ng/mL in Group E. This study showed that while all 
groups without indication of infection had initial PCT values that were slightly higher 
than non-infected non-cirrhotic patients (LUMItest reference range PCT <0.3 ng/mL), 
PCT values from groups A, B, C, and E were significantly lower than the PCT values of 
the cirrhotic patients with infection (Group C) (Elefsiniotis et al., 2006). 
Summary 
 All of the above studies, with the exception of the Spahr study, indicated that PCT 
can be used to presumptively identify a bacterial infection in patients with liver disease. 
However, none of the studies included patients with the most severe, acute liver disease, 
those with ALF or ALI. The Elefsiniotis study looked at some acutely ill liver disease 
patients some of whom might have met the diagnostic criteria of ALF or ALI, but none of 
the groups as a whole appeared to have met the diagnostic criteria. All of the above 
studies were small and none looked at how PCT relates to the severity of infection in 
patients with ALF or ALI. In addition, none of the studies explored whether or not 
SPCTCs change in response to successful treatment of bacterial infection in acute liver 
disease patients. 
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Significance of This Study 
 Procalcitonin appears to be a robust marker for bacterial infection. The above 
studies have shown that SPCTC is a good indicator of infection in the general population 
and is useful in monitoring antimicrobial therapy. However, it has not been extensively 
studied in the setting of acute liver injury or liver failure. The present proposed study 
investigated how SPCTCs vary in patients with ALF and ALI depending upon the 
severity of illness. Next, it will examine the utility of serum PCT concentrations as an 
indicator of bacterial infection in ALF and ALI patients. Lastly, the study investigated 
whether serum PCT values differ between ALF and ALI patients who are treated for 
bacterial infection and who achieve transplant free survival (alive at 21 days without 
transplant) and those treated for bacterial infection and who had a liver transplantation or 
died within the 21 day period of ALF or ALI study. 
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CHAPTER 3:  METHODS 
 
 This chapter describes the research design, methodology, and analyses used to 
determine whether procalcitonin is effective as a biomarker of infection/sepsis in the 
ALF/ALI patient populations. The ALF and ALI databases, sample selection, and 
independent and dependent variables in each section of the study are described. Statistical 
methods used to analyze the data are described. Limitations of the study are discussed.   
Research Design 
 This study was a retrospective, non-experimental study with three parts. A true 
experimental study was impractical due to the low incidence of ALF and ALI cases in the 
general population. Because the study used retrospective data and samples, the 
independent variable for this study, infection, could not be manipulated, fitting the 
description of non-experimental as described by Polit and Beck (Polit & Beck, 2008). 
Specific Aim 1 of the study examined the relationship between the severity of infection 
and SPCTC. Specific Aim 2 examined the relationship between the presence or absence 
of infection and SPCTC. Finally, Specific Aim 3 examined the differences in SPCTCs 
between infected ALF and ALI patients with transplant free survival (TFS - alive at 
discharge or 21 days) and infected ALF and ALI patients who died or received a liver 
transplant (DoT) within 21. The changes in the SPCTC values across the seven days of 
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the ALF/ALI study specimen collection were also compared between the TFS and DoT 
subjects.  
Specific Aims, Hypotheses, and Study 
There are three main aims for this study: 
Specific Aim 1:  To determine if 1) there are differences in SPCTCs between non-
infected ALF and ALI patients and non-infected chronic liver disease patients, 2) 
between infected and non-infected ALF and ALI patients, and 3) between ALF 
and ALI patients and those of the general population with different severities of 
infection. 
As noted by O’Grady, et al. (2008) and Harbarth, et al. (2001), SPCTCs can be used to 
denote the severity of infection in patients with definite or suspected bacterial infections. 
Can PCT be used in the ALF/ALI patient population to detect bacterial infections? Does 
liver disease affect the SPCTCs of liver disease patients with or without infection? 
H0:  There is no difference in SPCTCs between non-infected ALF/ALI patients 
and non-infected chronic liver disease patients. 
 H0:  There is no difference in SPCTSs between non-infected patients with liver 
disease (chronic and ALF/ALI) and non-infected patients in the general 
population (i.e., SPCTC <0.1 ng/mL. 
H0:  There is no difference in SPCTC between ALF/ALI patients with different 
degrees of severity of infection (i.e., Neg SIRS, SIRS, sepsis, severe sepsis, and 
septic shock). 
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These hypotheses were tested by measuring SPCTC in ALF/ALI patients with a 
documented history of infection, ALF/ALI without an infection, and chronic liver disease 
patients without an infection. The results were analyzed according to the presence or 
absence of infection and according to the severity of infection status based upon clinical 
signs and symptoms. 
 Specific Aim 2:  Determine the utility of SPCTC as a screening biomarker for 
 infection in ALF/ALI patients 
Does a change in SPCTC predict the onset of bacterial infections/sepsis in the ALF/ALI 
patient population?  
H0:  There is no difference in SPCTC in ALF/ALI patients between the first day a 
positive culture was collected and the three days prior to the positive culture. 
By measuring SPCTC on the days prior to diagnosis of infection and on the day of 
infection, we determined if PCT will give an earlier indication of infection than clinical 
symptoms. 
Specific Aim 3:  Determine if SPCTC in ALF and ALI patients with bacterial 
infection on Day 1 of the ALF or ALI study is associated with patient outcomes. 
Can changes in PCT be used to monitor progression or resolution of bacterial infection in 
the ALF/ALI patients?  
 H0:  There is no difference in SPCTC between ALF and ALI patients with a 
bacterial infection/sepsis who have transplant free survival and those who die or 
receive a liver transplant. 
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H0:  There is no difference in changes in the serial SPCTCs between ALF/ALI 
patients with a bacterial infection/sepsis who have transplant free survival and 
those who die or receive a liver transplant. 
By measuring SPCTC in ALF and ALI patients who have known infections, we 
determined if there were differences in the SPCTC between patients who died or received 
a liver transplant and those with transplant free survival. In studies of SPCTC in subjects 
with pathologies other than liver disease and sepsis/bacterial infections, monitoring 
SPCTC has shown the ability to successfully decrease the length of antibiotic use 
(Bouadma et al., 2010; Kollef, 2010).  We analyzed serial SPCTC in patients who were 
diagnosed with infection/sepsis on Day 1 of study and compared the results between 
those with transplant free survival and those who died or received a liver transplant. 
Changes in the serial values will also be analyzed to determine if there are differences 
between the two groups.  
Databases 
 Samples and data were obtained from four liver disease sample repositories and 
databases maintained by the University of Texas Southwestern Medical Center (UTSW) 
(Table 6). Acute liver disease samples and data were obtained from the ALF and ALI 
databases and sample repositories. Chronic liver disease data and samples were obtained 
from the Liver Disease database and sample repository and from the Nucleic Acid, 
Serum, and Tissue Repository for the Study of Liver Diseases database and sample 
repository. 
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Table 6:  Databases 
Database 
Collection 
Started Description 
Subjects 
Enrolled 
Prior to   
10-1-10 
Acute Liver Failure Jan. 1998 A multi-center NIH supported study 
to collect clinical information, 
serum/plasma, DNA, and tissue 
samples from patients with ALF  
1700 
Acute Liver Injury Oct. 2008 A multi-center NIH supported study 
to collect clinical information, 
serum/plasma, DNA, and tissue 
samples from patients with ALI 
163 
Liver Disease Database Dec. 2005 An Investigator initiated study at 
UTSW to collect information and 
serum/plasma samples from subjects 
who may qualify for clinical trials or 
are at high risk for developing liver 
disease. 
475 
Nucleic Acid, Serum, 
and Tissue Repository 
for the Study of Liver 
Diseases  Database 
1996 Investigator initiated study at UTSW 
to collect data/samples to support 
translational research in liver 
diseases.  
206 
 
Acute Liver Failure Database 
 The U.S. Acute Liver Failure Study Group (USALFSG) was established in 1998 
with pilot funding from the FDA and supported by the National Institute of Health (NIH) 
continuously since that time. The group proposed two aims: to prospectively collect 
detailed clinical information, serum, DNA, and tissue samples from patients with ALF 
and to develop controlled trials of innovative therapies for ALF (Lee et al., 2008; Lee & 
Seremba, 2008). The USALFSG is currently composed of 13 clinical sites, reduced from 
a maximum of 23 clinical sites prior to 2010. From January 1998 to October 2010, 1700 
adult ALF patients have been prospectively enrolled in the study. Inclusion criteria 
52 
 
 
 
defining ALF are the presence of coagulopathy (PT > 15 seconds or INR >1.5) and any 
grade of hepatic encelphalopathy (HE) that occurs within 26 weeks of the first onset of 
symptoms. The patients may not have any previously diagnosed liver disease, with the 
exception of chronic hepatitis B or Wilson’s disease as defined earlier (Lee et al., 2008). 
Due to the altered mental status of the patients caused by HE, informed consent must be 
obtained from the next of kin to be enrolled in the ALF study. 
 Patients are enrolled into the ALF study for a maximum of 21 days with two 
annual follow-up visits. Clinical and demographic information, medical history, and 
medication history are obtained from the medical record for days 1 – 7 and 21 (or day of 
discharge, transplant, or death) and at each follow-up visit. The information is recorded 
on the study case report form (CRF). If required, information may be requested from the 
patient’s primary care physician, once a signed medical records release form is obtain. 
All information is entered into the USALFSG database.  
 Blood samples are collected on days 1 – 7, unless the patient is discharged, dies, 
or is transplanted. The blood samples are centrifuged to remove the cells and 500 µL 
aliquots of serum or plasma are frozen at -20
o
 C or colder in small cryo vials. Samples are 
stored at the collecting facility until sent to the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) sample repository. The NIDDK repository 
stores the samples at -70
o
 C. 
Acute Liver Injury Database 
 The Acute Liver Injury Study is an extension of the ALF study in which patients 
present to the hospital with acute liver disease but do not exhibit any signs of hepatic 
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encephalopathy at the time of admission. If encephalopathy occurs during the course of 
the study, the patient may be consented and enrolled in the ALF study. In this case, the 
data would then be collected using the ALF protocol. The purpose of the ALI study, like 
the ALF study, is to collect clinical information, serum, DNA, and tissue samples from 
patients with ALI, and to develop controlled trials of innovative therapies for ALI. The 
ALI subjects are prospectively enrolled into the study at the same clinical sites that are 
enrolling ALF patients. The data and sample collection plan is similar to that described 
for ALF. Data and blood samples are collected on days 1 – 7 (or until discharge, death, 
transplant, or transfer to the ALF study). Follow-up data is also collected at day 21, six 
weeks, and 12 weeks if possible. The ALI sub-study was started in October 2008 and has 
enrolled 163 subjects through September 2010. 
 Although the diagnostic criteria for acute liver injury are the same as for acute 
liver failure only without HE, the inclusion criteria for the ALI database differ slightly 
from those of ALF. The inclusion criteria for ALI are: serum ALT greater than or equal 
to 10 times the upper limit of normal, total serum bilirubin greater than or equal to 3.0 
mg/dL, coagulopathy (PT greater than 20 seconds or INR greater than 2.0), acute hepatic 
illness of less than 26 weeks and no evidence of encephalopathy. Patient with 
acetaminophen etiology should have hepatic illness of less than two weeks duration. 
Liver Disease Database 
 The primary purpose of the Liver Disease database (LDD) is to allow for contact 
between study personnel at the University of Texas Southwestern Medical Center at 
Dallas (UTSW) Clinical Center for Liver Disease (CCLD) and patients who have liver 
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disease and may wish to qualify for clinical trials or who are considered at high risk of 
developing liver disease (subjects with high risk behavior and spouses of patients with 
hepatitis). The secondary purpose of the database/sample repository is to provide serum 
samples for various liver disease research projects, and to characterize subjects based on 
their specific disease etiology such as viral hepatitis genotype. While the study enrolls 
subjects with all types of liver disease and some without apparent liver disease, it is 
composed primarily of subjects with viral hepatitis, predominantly hepatitis C. The study 
received initial IRB approval in December 2005, and has prospectively enrolled 475 
subjects as of Oct. 2010. 
 Once a patient is identified as a possible study subject and informed consent is 
properly executed, a short questionnaire is filled out. The questionnaire is used to collect 
demographic information including contact information and liver disease etiology. If the 
subject consents, a blood sample is collected so that serum and plasma can be stored for 
later use to categorize the subject or for research protocols involving liver disease. The 
subject may elect to not have a blood specimen collected at the time of enrollment but 
may be asked to have one collected at a later time if they are interested in a potential 
treatment study and wish to be pre-screened for the trial. Remnant samples are stored for 
future testing. The blood samples are centrifuged to remove the cells and 500 µL aliquots 
of serum or plasma are frozen at -20
o
 C
 
or colder in small cryo vials. Samples are stored 
at UTSW Liver Research Laboratory at -70
o
 C. 
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Nucleic Acid, Serum, and Tissue Repository for the Study of Liver Diseases Database 
 The primary purpose of the Nucleic Acid, Serum, and Tissue Repository for the 
Study of Liver Diseases (NSTLD) study is to gain a better understanding of possible 
causes of the development and progression of liver diseases in order to develop new 
treatments. The data/sample repository provides support for translational research in liver 
diseases within the UTSW Division of Digestive and Liver Diseases. While the study 
enrolls subjects with all types of liver disease and controls, the database is composed 
primarily of subjects with primary biliary cirrhosis. The study received initial IRB 
approval in 1996, and has prospectively enrolled 206 subjects as of Oct. 2010. 
 Once a patient is identified as a possible study subject and informed consent is 
properly executed, a short questionnaire is filled out. The questionnaire is used to collect 
demographic information including contact information and liver disease etiology. Blood 
and tissue samples are collected as part of this study. The blood samples (for obtaining 
serum or plasma collection) are centrifuged to remove the cells and 1000 µL aliquots of 
serum or plasma are frozen at -70
o
 C
 
or colder in small cryo vials. Samples are stored at 
the UTSW Department of Digestive and Liver Diseases Laboratory at -70
o
 C. 
Sampling  
 This study has three components. Each part of the study is related to one of the 
three specific aims. Sample populations are described for each group.  
Specific Aim One 
 The first step requires the identification of the patient samples used for this 
section of the study. As described above, a patient can be classified as having SIRS, 
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sepsis, and severe sepsis based upon their clinical biodata. An algorithm (see Appendix 
A) based upon the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions 
Conference definitions of SIRS, sepsis, severe sepsis, and septic shock was used to 
determine which classification each subject fit into during each of the first seven days of 
the study for all subjects in both the ALF and ALI databases. The algorithm was based 
upon the available data contained in the databases.  
 Subjects with SIRS, by definition, have two or more of the following signs or 
symptoms: body temperature >38
o 
C or <36
o 
C, heart rate >90 bpm, respiration rate >20 
breaths/min, PCO2 level <32 mm Hg, WBC >12,000 or <4,000, or bands (immature 
granulocytic white blood cells) >10%. The ALF and ALI databases do not collect data for 
heart rate and respiration for all seven days and does not routinely collect data on bands. 
These parameters were not used to identify patients with SIRS but were used to identify 
patients without SIRS.  
 Sepsis is defined as the presence of SIRS plus a documented infection or the 
presence of at least one of the following signs or symptoms: edema or positive fluid 
balance, glucose >120 mg/dL in the absence of diabetes, elevated CRP or PCT values, a 
SVO2 >70%, or a cardiac index of >3.5 L/min/M
2
. In the case of the ALF and ALI 
databases, none of the signs and symptoms data were collected on all days of the study. 
Therefore, a classification of sepsis was made only when a patient had a SIRS 
classification plus a confirmed infection (positive culture). Positive bacterial cultures are 
considered the gold standard for infection, although this strict criterion may also miss 
certain infections where a positive culture is not obtained for a variety of technical 
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reasons. The presence of yeast and fungal infections was captured in the infection data 
but was excluded from the analysis because a positive bacterial culture was used as the 
indication of an infection. There is published evidence that yeast and fungal infections 
cause an increase in SPCTC but at a lower level than those of bacterial infections 
(Dornbusch et al., 2005; Martini et al., 2010; Nakamura, Wada, Takeda, & Nobori, 
2009). 
 Severe sepsis is defined as organ failure in the presence of sepsis. Because a 
diagnosis of organ failure (i.e. liver failure) has already been made by definition in the 
ALF population, all ALF patients would automatically be classified as severe sepsis. For 
the purposes of this study, subjects were not categorized into the severe sepsis group if 
only liver failure was noted. A subject was classified into the severe sepsis category if 
any additional type of organ failure other than liver failure was noted. Table 7 lists the 
various biodata parameters used to denote organ failure and the type of organ failure 
suggested by the parameter. The parameters acute oliguria, prolonged aPTT, and 
diminished blood pressure as noted in the previous discussion, were not used as 
information relevant to these parameters was not consistently collected for all days of the 
study.  
Septic shock is defined as the presence of severe persistent hypotension despite 
adequate volume resuscitation (Levy et al., 2003) in the presence of sepsis. Because the 
majority of the patients in this group were in the intensive care unit of the hospital, an 
assumption of adequate fluid resuscitation was made (treatment for hypotension). A MAP 
of <60 mmHg while on pressor therapy was used as an indicator of persistent  
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Table 7:  Severe Sepsis Signs and Symptoms  
Severe Sepsis 
Parameter Organ system 
Arterial hypoxemia PaO2/FiO2 ratio  
<300 torr  
Respiratory 
Creatinine  
>0.5mg/dL increase above baseline 
Kidney 
Coagulation abnormalities  
INR >1.5  
Coagulation - blood 
 
Thrombocytopenia  
platelet count <100,000 
Coagulation - blood  
Hyperbilirubinemia  
total bilirubin >4 mg/dL  
Liver 
Hyperlactatemia  
>1 mmol/L 
Blood 
MAP  
<70 mmHg 
Respiratory 
Altered mental status 
Coma Grade 
Central nervous system  
 
hypotension. Blood pressure parameters other than MAP were not utilized because 
information on these parameters was not collected on all days of the studies. 
 Non-infected/non-SIRS ALF/ALI (Neg SIRS) samples were selected from 
patients who met no more than one of the SIRS criteria. These samples were selected 
from Day 1 of the study so that all parameters (WBC, pulse, respiration, temperature, and 
pCO2) were available identify patients in this category. Samples with missing SIRS 
criteria data were excluded.  
 The data were organized into a Microsoft Excel 2007 spreadsheet (Microsoft, 
Redmond, WA) and condition statements (e.g., IF, AND, OR, etc.) were used to 
determine the status of each ALF and ALI patient on each day of study enrollment. The 
following guidelines were used to indicate a specific category: 
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 Neg SIRS – if less than two of the SIRS parameters were positive 
 SIRS – if any two of the SIRS parameters were positive 
 Sepsis – presence of a confirmed bacterial infection 
 Severe sepsis – the presence of organ failure other than liver 
 Septic shock – extreme hypotension with pressor therapy 
An individual subject may multiple categories during the course of the seven days of the 
study however, that subject was not used for more than one category.  
 Because the ALF and ALI studies are non-treatment studies that were not planned 
to specifically study the SIRS continuum and infection, specific data were not available 
for each patient on all days of the study. Some of the biodata parameters noted in the 
SIRS categories are not routinely collected by the ALF and ALI studies and the attending 
physician may not have required other parameters. For the 1863 patients enrolled in the 
ALF and ALI studies, there are 12,492 days of demographic and biodata information 
available. However, only 3.5% of all days that all patients were enrolled in the studies 
had complete data for all biodata parameters. Of those with complete biodata, only 80 
days had a documented infection. The sampling plan for Specific Aim 1 described below 
calls for 90 samples with a documented infection. Therefore, to maximize the availability 
of samples, missing data were treated as a null value (i.e., if a lab value was missing, it 
was considered to be negative for that parameter) for the purposes of categorizing the 
samples. A biodata parameter had to be present and fit the criteria definition to be 
considered positive. 
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 A power analysis was performed to determine an appropriate sample size. First, 
we estimated the effects of sample size using results from the literature (Giamarellos-
Bourboulis et al., 2002a) and log-transformed the means and standard deviations (log10) 
due to the large differences in variances for each group. A sample size estimate using a 
one-way ANOVA design with five levels (not infected, SIRS, sepsis, severe sepsis, and 
septic shock) resulted in an effect size of 0.65, a large effect by Cohen’s standards, 
(Cohen, 1977). Using this effect size estimate conservatively, a power analysis was 
conducted for a factorial design with two between factors at three (etiology: APAP, viral, 
and other) and 5 (infection categories) levels. Different infection groups were assumed to 
have a medium effect (0.30), different etiologies were assumed to have a small effect on 
the PCT values (0.15), and the interaction (etiology by infection) was assumed to have a 
small effect (0.15). A minimum of 10 observations in each of the 15 cells (3 x 5) for a 
total of 150 observations will achieve the following levels of power. An 83.8% power for 
the comparisons of the infection groups, 35.0% power for the comparisons of the 
etiologies, and 19.2% power for the interaction between etiologies and infection group 
will result using an F test assuming an alpha of 0.05. 
 After determining the SIRS status of each ALF and ALI subject on each day of 
study enrollment, samples were selected based upon the following schema described in 
Table 8. The ALF/ALI project manager was given a list of possible samples for each 
category. The project manager selected the appropriate number of samples from the list 
of possible samples for each category based upon sample availability. If a subject was in 
the same category for more than one day, only one day was used for that subject. The day  
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Table 8:  Categories and Numbers of Subjects Desired for Specific Aim One 
Classification 
Etiology of Liver Disease 
Total 
Classification Acetaminophen 
Viral 
hepatitis 
Other 
Etiologies 
Chronic/ non-ALF, not infected na 10 10 20 
Neg SIRS, not infected 10 10 10 30 
SIRS, not infected 10 10 10 30 
Sepsis 10 10 10 30 
Sever sepsis 10 10 10 30 
Septic shock 10 10 10 30 
Total etiology 50 60 60 170 
  
tested was the first day the subject fell into the category for which a serum sample was 
available. Subjects from the Liver Disease and NSTLD databases were outpatients and 
were considered to have less severe liver disease than the hospitalized ALF and ALI 
subjects, negative for SIRS criteria, and classified as not infected. The chronic/non-
ALF/non-ALI subject category does not have an acetaminophen etiology since liver 
disease caused by an overdose (either accidental or intentional) of acetaminophen is 
acute, not chronic in nature. 
 The subjects were distributed between the different etiologies so that all types of 
acute liver failure/injury were represented in the study. Etiologies were examined to 
determine if they resulted in differences in SPCTC results. The SPCTC results from the 
chronic group and the non-infected groups were compared to the published SPCTC 
reference range for non-infected individuals (SPCTC <0.1 ng/mL) to determine if there is 
a different reference range for patients with liver disease.   
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Specific Aim Two 
 Forty-five subjects who had a positive bacterial culture identified on days four, 
five, six, or seven in either ALF or ALI study were selected for SPCTC measurement. A 
list of potential subjects was generated. The AFL/ALI project manager selected the 
subjects based upon sample availability. Samples were obtained from the day of the 
positive bacterial culture and from each of three preceding days and analyzed for SPCTC.  
Specific Aim Three 
 Subjects who had a positive bacterial culture on Day 1 of the study were 
categorized based upon their end of ALF or ALI study outcome. The subjects in this 
section of the study were categorized as having either transplant free survival (TFS) or 
death or liver transplant (DoT) by Day 21. If patients were placed on the liver transplant 
wait list, this factor alone was not considered a bad outcome because a patient might have 
improved and removed from the list. United Network for Organ Sharing (UNOS) status 
one criterion is limited to ALF patients (sudden and severe onset of liver failure) and 
states that a patient has a high likelihood of dying within seven days ("Questions and 
answers for transplant candidates", 2008). If a patient was placed on the liver transplant 
wait list and remained on the wait list through day 21, this patient was excluded from 
either category. A list of subjects that fit each group was generated. The ALF/ALI 
biodata manager selected 30 subjects from each group (TFS or DoT) based upon which 
samples had the most available volume. One blood sample from each of the seven 
sampling days each subject was enrolled in the ALF or ALI studies was requested (if 
available).  
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Testing 
Specimen Procurement and Retrieval 
 A list of samples from each section of the study was given to the USALFSG 
coordinator in charge of the sample repository to determine the availability of samples. 
Once sample availability was confirmed, a list of the requested samples was sent to the 
NIDDK. The NIDDK retrieved the requested samples and shipped them to study 
personnel at Siemens Healthcare Diagnostics in Tarrytown, NY for testing. In some 
cases, if a specimen was requested for more than one specific aim, the SPCTC results 
from one specimen were utilized for all specific aims. Frozen samples were shipped on 
dry ice using a commercial carrier. Upon receipt by study personnel at UTSW, the 
samples were stored at -70
o
 C until testing. Samples from the LDD and NSTLD sample 
repositories at UTSW were also shipped on dry ice to Tarrytown, NY by commercial 
courier for testing. 
ADVIA Centaur Immunoassay Analyzer Testing 
 The ADVIA Centaur system uses a Master Curve and two-point calibration to 
calibrate quantitative assays such as the PCT assay. The master curve is established as 
part of the manufacturing process. Full standard curves are performed on a lot number of 
PCT reagent on multiple instruments at multiple concentration levels. The RLUs at each 
level is determined. The concentrations of the standards and the RLUs at each 
concentration are used to generate a master curve for that lot. The PCT assay is a 
sandwich assay that produces a calibration curve that has a positive slope. To minimize 
instrument-to-instrument variability, reagent age, and environmental factors, a two-point 
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calibration is performed when a new lot of reagent is installed on the instrument, at 
specified intervals (35 days for PCT), and as needed (example: out of range control 
values or major maintenance procedures). Replicates of two defined calibrators are 
measured on the instrument using the assay sequence described below. If the mean RLU 
values for the calibrators meet defined validity criteria, the system compares the 
calibrators to the Master Curve for the lot of PCT reagent and determines a system-
specific formula for the lot of PCT reagents. The system then uses that lot/system-
specific formula to determine the PCT values of subsequently run controls and patient 
samples ("Advia centaur reference manual", 2003).  
The ADVIA Centaur BRAHMS PCT ("Advia centaur systems - procalcitonin 
(PCT)", 2010) assay is a sandwich immunoassay composed of solid phase, lite reagent, 
and ancillary reagents. The solid phase reagent contains a monoclonal mouse antibody to 
fluorescein covalently linked to paramagnetic particles. The lite reagent contains a 
monoclonal mouse antibody to procalcitonin that is labeled with acridinium ester. The 
ancillary reagent contains a monoclonal mouse antibody to procalcitonin labeled with 
fluorescein (Figure 2).  
 
 
Figure 2:  Siemens PCT Reagent Components  
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Serum samples were thawed, mixed and placed in bar-coded sample holders and 
racks that were then placed on the Centaur for analysis. The ADVIA Centaur is a random 
access analyzer that can produce 270 PCT results in approximately two hours. Samples 
were tested in three groups (based upon which specific aim the sample was selected for) 
over the course of four days. Quality control samples (ADVIA Centaur BRAHMS PCT 
quality control samples 1 and 2) were run in triplicate at the beginning and end of testing 
on each day of testing. The first set of samples tested were those for Specific Aim 1. The 
second and third sets of samples tested for were for Specific Aims 2 and 3, respectively. 
Samples requiring a dilution, a result above the analytical range or due to low sample 
volume, were tested on the fourth day using a manual dilution. Results were calculated 
from the reported result by multiplying by the appropriate dilution factor.  
 The ADVIA Centaur system automatically processed samples to be tested for 
PCT in the following sequence: 
1. Combines 100 µL sample and 45 µL ancillary reagent incubates the mixture for 
5.75 minutes at 37
0
 C (Figure 3) 
 
 
Figure 3:  Sample + Ancillary Reagent  
 
2. Adds 100 µL of solid phase and 50 µL of lite reagent to the mixture and incubates 
for 18 minutes at 37
o
 C (Figure 4) 
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Figure 4:  Add Solid Phase and Lite Reagent   . 
 
3. Aspirates the unbound reagent, holding the solid phase in place in the reaction 
cuvette by means of a magnet  
4. Washes the solid phase with Wash 1 solution (a phosphate buffered saline with 
sodium azide (<0.1%) and surfactant)   
5. Aspirates the Wash 1 solution while holding the solid phase in the reaction 
cuvette by means of a magnet.  
6. Adds 300 µL of Acid Reagent to start a chemiluminescent reaction with the 
acridinium ester. 
7. Moves the reaction cuvette into the luminometer and adds 300 µL Base reagent 
completing the chemiluminescent reaction producing a flash of light. 
8. The luminometer measures the intensity of light produced by the 
chemiluminescent reaction. The light is measured in relative light units (RLUs) 
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The amount of RLUs detected by the system is directly proportional to the amount of 
PCT present in the patient sample ("Advia centaur immunoassay system reference 
manual", 2003). The measuring range is 0.02 to 75 ng/mL.  
 Because of regulations restricting use of reagents that have been submitted to the 
FDA but have not been approved for use, testing was performed at Siemens Healthcare 
Diagnostics in Tarrytown, NY. A single ADVIA Centaur was made available for use 
during the four days required for testing. Siemens Healthcare Diagnostics, Tarrytown, 
NY, provided all reagents required for testing. 
 The assigned analyzer was calibrated using a 2-point Master Curve calibration. 
The master curve and calibrator values were entered into the Centaur computer system 
and low and high calibrators with known values were assayed in triplicate as required for 
calibration of a new lot of reagent. The average observed RLU values from the 
calibrators were compared to the Master Curve and a system-specific formula was 
generated. Patient and quality control samples were assayed and the observed RLU 
values were adjusted using the generated system-specific formula to obtain adjusted 
RLUs that were then compared to the Master Curve to obtain the final PCT 
concentrations. Samples with values greater than 75 ng/mL were manually diluted using 
Multi-Dil 1 ancillary reagent and the diluted samples were re-assayed as described above. 
Statistical Analysis 
 Laboratory data from the databases were entered into Microsoft Excel 2007 
spreadsheets. These data were merged with the procalcitonin data and analyzed using 
68 
 
 
 
SPSS 19.0 (SPSS Inc., Chicago, IL, 2010) and SAS 9.2 (SAS Institute Inc., Cary, NC, 
2008). 
Descriptive statistics are included with the analysis of all sample data for all 
groups. In the study, Specific Aim 1 addressed whether SPCTC (the dependent variable) 
can be used to detect bacterial infections in patients with ALF and ALI. Subjects were 
categorized by ALF etiology and infection with the level of infection based upon 
SIRS/sepsis criteria (the independent variables). A Kruskal-Wallis test with post hoc 
testing (Dunn Method) for non-parametric parameters was used to analyze the data to 
determine if SPCTC can be used to detect infection, if there is a difference between 
SPCTC in patients with chronic liver disease and ALF and ALI, and indicate the severity 
of infection in ALF and ALI patients.  The chronic group and the non-infected groups 
(Neg SIRS and SIRS) means were compared to the reference range of the PCT assay. An 
expected value of <0.1 ng/mL was calculated from PCT values from a population of 456 
normal subjects. The 95% confidence interval for the mean concentration was 0.023 to 
0.028 ng/mL ("Advia centaur and advia centaur XP systems - procalcitonin (PCT)", 
2010).  
A Chi-square test was used as an alternative method for analyzing the Specific 
Aim 1 hypothesis. Use of chi-square required re-categorizing the samples into infection 
and non-infection groups. SPCTC results were dichotomized based upon a cut-off value 
indicative of infection. ROC analysis was used to determine the optimal cutoff value that 
separates the specimens from the infected and non-infected subjects. The optimal cut-off 
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value was defined as the point on the curve where the perpendicular distance from (and 
above) the 45
O
 line of equality is at maximum (Riffenburgh, 2006).     
Specific Aim 2 addresses the use of SPCTC as a screening marker for bacterial 
infection in ALF and ALI patients by determining the SPCTC (the dependent variable) 
on the day of identified bacterial infection and comparing it to the SPCTC for the three 
days prior to infection. The presence or absence of infection is the independent variable 
for this specific aim. The day of identified infection is positive, while the previous three 
days are assumed to be negative. Data pertaining to Specific Aim 2 were analyzed using a 
Friedman test for non-parametric related samples to determine if SPCTC can be used as a 
screening biomarker in ALF and ALI subjects who develop a bacterial infection.  
Specific Aim 3 addresses the use of SPCTC to predict outcomes in ALF and ALI 
patients with a bacterial infection. Subjects were categorized as having transplant free 
survival or death or transplant outcomes (the independent variable). SPCTC (the 
dependent variable) values for each day of the seven day study period were determined. 
Data for Specific Aim 3 were analyzed using a mixed models analysis of covariance. The 
following variables were explored to determine their significance in the model:  visit day, 
outcome (TFS or DoT), diagnosis (APAP vs. All Other Etiologies), severity of illness 
(sepsis, severe sepsis, and septic shock), antibiotic therapy (prescribed or not prescribed), 
antibiotic prophylaxis (prescribed or not prescribed), antibiotic use (prophylaxis and/or 
therapy - prescribed or not prescribed), and coma grade (1 and 2 (mild) vs. 3 and 4 
(severe)). The results of the analyses were used to determine if mean SPCTC levels were 
different when accounting for features related to bacterial infection in ALF patients. 
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CHAPTER FOUR:  RESULTS 
 
 This chapter describes the results from the statistical analysis of the data and 
explores the relationship between SPCTC and severity of illness, determines if SPCTC 
can detect infection, and determines if SPCTC was related to the final outcome in ALF 
and ALI patients. A brief summary of statistics related to the ADVIA Centaur BRAHMS 
assay will also be presented. For each specific aim, a description of how the samples 
were selected will be presented along with descriptive statistics for each group of 
samples. This will be followed by an overview of the results. Finally, detailed analyses 
for each hypothesis will be presented. The statistical analyses and graphics prepared for 
this study were performed using SPSS 19, SAS 9.2, Microsoft Excel 2007, and 
SigmaPlot 12.0 (Systat Software, Inc. San Jose, CA). 
 Institutional Review Board (IRB) approval was obtained from the University of 
Texas Southwestern Medical Center (IRB#STU092010-126) and Virginia 
Commonwealth University (IRB#HM13517). Study subjects were patients who had 
previously consented to enrollment into one or more of the following studies:  ALF, ALI, 
LDD, or NSTLD. 
Assay Statistics 
 ADVIA Centaur BRAHMS PCT assay is sandwich immunoassay developed for 
use with the ADVIA Centaur analyzer. The PCT assay was developed to aid in the 
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detection and monitoring of infection and sepsis in patients suspected of having a 
bacterial infection. ADVIA Centaur BRAHMS PCT low and high controls were run in 
triplicate each day after the initial calibration at the beginning of the sample set (morning) 
and at the end of the set (afternoon) on testing days one, two, and three. The controls 
were run only in the morning on day four as the run was completed within an hour. All 
control values fell within the prescribed ranges. The control values were used to calculate 
within-run and between-run means, standard deviations, and coefficient of variations 
(Table 9). Overall, the assay performed to the manufacturer’s specifications. However, 
the CVs for this study were less than the CVs previously reported for the ADVIA 
Centaur BRAHMS PCT and the KRYPTOR PCT (between-run:  3.6% to 8.6% and 
within-run:  1.1% to 6.1%) (Aso, et al., 2009) . 
Table 9:  PCT Assay Imprecision 
Control Assigned All Runs With-in Run CV Between- 
 Range Mean SD Lowest Highest Run CV 
Low (ng/mL) 0.221 – 0.663 0.40 0.014 0.67 2.93 3.41 
High (ng/mL) 7.30 – 13.7 10.06 2.19 0.48 1.26 2.19 
.  
Specific Aim One 
 The purpose of Specific Aim 1 was to measure SPCTCs in infected and non-
infected ALF and ALI patients to determine whether values observed were the same or 
different from the PCT ranges based upon the severity of infection noted in previous 
studies in the general population.  
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Sample Selection 
 Data from 1863 ALF and ALI cases (1829 patients – 34 were initially enrolled in 
the ALI study, subsequently developed HE, and were enrolled into the ALF study) were 
entered into an Excel 2007 spreadsheet. The clinical biodata on each available day for 
each subject was examined and sorted using an algorithm (see appendix A) to classify 
each patient-day as representing either SIRS, sepsis, severe sepsis, or septic shock. Data 
from 12,492 patient-days were sorted into the above categories. Because heart rate and 
respiration were collected only on Day 1, only biodata from Day 1 were analyzed for the 
Neg SIRS category. Table 10 presents the total number of patient-days identified for each 
severity category. The project manager randomly selected samples for each etiology for 
all severity categories based upon availability of serum samples in the sample repository. 
Table 11 presents the actual number of patient-days in each category and etiology. 
Table 10:  Category and Sample Availability of ALF and ALI subjects 
Category Description 
Number Patient 
Days Available 
Neg SIRS 
(Day 1) 
Less than 2 of SIRS values positive 628 
SIRS 
(Days 1 – 7) 
2 or more SIRS values positive  1407 
Sepsis 
(Days 1 – 7) 
SIRS with a confirmed infection and only 
liver dysfunction 
39 
(from 29 patients) 
Severe Sepsis 
(Days 1 – 7) 
SIRS with a confirmed infection and 
multiple organ dysfunction 
348 
Septic Shock 
(Days 1 – 7) 
SIRS with a confirmed infection and a 
MAP < 60 
31 
(from 25 subjects) 
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Table 11:  Number of Subjects Tested for PCT Based Upon Severity Category and ALF 
Etiology 
 
Classification 
Etiology of Liver Disease 
Total 
Classification Acetaminophen 
Viral 
hepatitis 
Other 
Etiologies 
Chronic/ non-ALF, 
not infected 
na 10 10 20 
Neg SIRS, not infected 10 10 10 30 
SIRS 10 10 9 29 
Sepsis 6 1 6 13 
Sever sepsis 10 6 11 27 
Septic shock 5 1 10 16 
Total etiology 41 38 56 135 
 
 The sepsis group and the septic shock group had fewer available samples than the 
other categories. There are multiple possible reasons for this. The ALF patient population 
were critically ill. Samples and data were collected only once every 24 hours for the ALF 
and ALI studies and the patients’ conditions could change within hours. In some cases, 
samples were either not collected on a given day or the supply of aliquots had been 
depleted. Single organ dysfunction (i.e., liver only) is extremely rare in this population. 
The same is true of septic shock. The septic shock patients are at the most severely ill end 
of the spectrum of illness. It is possible that more subjects may have actually fit into this 
category, but died or underwent liver transplantation before the next day’s sample was 
collected. The apparent low number of viral hepatitis subjects in three of the categories 
reflects the small number of viral hepatitis cases (approximately 12%) among both ALF 
and ALI registries, while APAP accounts for approximately 50%. All other etiologies 
account for approximately 38%. 
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 Available demographic and biodata information were obtained from the LLD and 
NSTLD databases for patients with chronic liver disease. In the case of the LLD 
database, information was limited to demographic information. The NSTLD database did 
have demographic information and biodata, but the amount of biodata was not as 
extensive as the biodata collected in the ALF or ALI databases. Because the NSTLD 
subjects were ambulatory (outpatients), it was assumed that the likelihood of them having 
an infection was extremely small and were classified as not infected.  
Demographic Information 
 Differences in demographic information, biodata, and laboratory values among 
the severity categories were determined using one-way ANOVA for determining 
differences between group means or a 2-sided Fisher’s Exact test for determining 
differences between group percentages at a statistical significance level of 0.05. A 
summary of the demographic information for each infection group is described in Table 
12. There were significant differences in the ages (p-value = 0.030) and gender (p-value 
= 0.029), but not in race (p-value = 0.479) of the subjects among the infection groups. 
However, there was a higher percentage of females and caucasians than males and other 
races in the study over all.  
 There was considerably more variation in the biodata and laboratory data among 
the categories (Table 13). Pulse and respiration were significantly different between the 
categories as expected since they reflect severity of illness (p-value = 0.001 for each) 
while temperature and MAP were not. Note:  The Septic Shock MAP was not included in  
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Table 12:  Demographic Data for Patients Based Upon Severity of Illness Classifications 
Mean (± SD) or 
Number (%) 
Chronic 
n = 20 
Neg 
SIRS 
n = 30 
SIRS 
n = 29 
Sepsis 
n = 13 
Severe 
Sepsis 
n = 27 
Septic 
Shock 
n = 16 p-value 
Age (years) 
53.8  
(±9.4) 
47.2 
(±16.0) 
40.5  
(±15.8) 
42.9  
(±15.8) 
40.7  
(±12.5) 
45.4  
(±17.2) 
0.030 
Gender 
      
 
Female 10 (50) 15 (50) 21 (72.4) 12 (92.3) 21 (77.8) 12 (75) 0.029 
Ethnicity* 
      
 
Hispanic 
 
5 (16.7) 5 (17.2) 2 (15.4) 3 (11.1) 1 (6.7)  
Race* 
      
 
White 14 (77.8) 21 (66.7) 23 (79.3) 9 (69.2) 24 (88.9) 14 (87.5) 0.479 
African American 1 (5.6) 5 (16.7) 5 (17.2) 1 (7.7) 3 (7.7) 1 (6.2)  
Asian 2 (11.1) 2 (6.7) 1 (3.4) 2 (15.4) 
 
1 (6.2)  
Hawaiian 
 
1 (3) 
    
 
Other 1 (5.6) 1 (3) 
 
1 (7.7) 
  
 
Diagnosis 
      
 
APAP 
 
10 (33.3) 10 (34.5) 6 (46.2) 10 (37.0) 5 (31.2)  
Viral Hepatitis 10 (50) 10 (33.3) 10 (34.5) 6 (46.2) 6 (22.2) 1 (6.2)  
Other 10 (50) 10 (33.3) 9 (31.0) 1 (7.7) 11 (40.7) 10 (62.5)  
Outcome (TFS) 
      
 
APAP 
 
6 (20) 5 (17.2) 5 (38.5) 7 (25.9) 1 (6.2)  
Viral Hepatitis 
 
4 (13.3) 2 (6.9) 
 
2 (7.4) 
 
 
Other 
 
1 (3.3) 4 (13.8) 2 (15.4) 3 (11.1) 1 (6.2)  
Coma Grade 
      
 
Not Reported / 0 20 (100) 
 
4 (13.8) 1 (7.7) 2 (7.4) 
 
 
1 
 
11 (36.7) 1 (3.4) 3 (23.1) 1 (3.7) 
 
 
2 
 
11 (36.7) 8 (27.6) 1 (7.7) 
  
 
3 
 
4 (13.3) 5 (17.2) 2 (15.4) 9 (33.3) 1 (6.2)  
4 
 
4 (13.3) 11 (37.9) 6 (46.2) 15 (55.6) 15 (93.8)  
Culture Types 
      
 
Blood – 1 
   
1 5 5  
Tracheal – 2 
   
6 6 4  
Urine – 3 
   
2 3 3  
Wound – 4 
   
1 2 1  
Catheter – 5 
    
1 
 
 
Multiple w Blood – 7 
   
2 8 2  
Multiple wo Blood – 8 
   
1 2 1  
Antibiotics Used 
 
19 (63.3) 23 (79.3) 11 (84.6) 22 (81.5) 13 (81.2) 0.471 
Prophylaxis 
 
15 (50) 17 (58.6) 5 (38.5) 14 (51.9) 10 (62.5) 0.718 
Therapy 
 
7 (23) 12 (41.4) 7 (53.8) 15 (55.6) 7 (43.8) 0.122 
Age of Sample  
(years) 
8.4  
(± 5.6) 
6.6  
(± 3.3) 
6.8  
(± 3.0) 
7.2  
(± 3.1) 
6.3  
(± 3.2) 
6.2  
(± 2.9) 
0.380 
After Hospital 
Admission (days) 
 3.9  
(± 2.7) 
8.6  
(± 10.3) 
5.8  
(± 3.4) 
8.2  
(± 5.5) 
7.2  
(± 6.2) 
0.002 
*Ethnicity: O were reported in the Chronic group; 15 of 16 were reported in the Septic Shock group 
Race:  18 of 20 reported in the Chronic group / p-value reported for white vs. all other races 
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Table 13:  Biodata and Laboratory Values for Patients Based Upon Severity of Illness 
Classifications 
 
 
Chronic Neg SIRS SIRS Sepsis Severe Sepsis Septic Shock p 
Mean (± SD) n = 20 n = 30 n = 29 n = 13 n = 27 n = 16 Value 
Pulse 
 
78 (± 18) 49 (± 56) 58 (± 63) 15 (± 38) 73 (± 60) 0.001 
Respiration 
 
16 (± 3) 11 (± 12) 11 (± 12) 3 (± 7) 14 (± 13) 0.001 
Min Temperature 
 
36.7 (± 0.8) 36.2 (± 1.5) 36.5 (± 1.3) 36.5 (± 1.1) 36.6 (± 1.4) 0.668 
Max Temperature 
 
36.8 (± 0.6) 36.6 (± 1.1) 37.2 (± 1.2) 37.7 (± 1.9) 37.3 (± 1.2) 0.098 
MAP 
 
84.4 (12.9) 84.2 (± 21.0) 92.3 (± 16.5) 88.8 (± 19.6) 53.4 (± 6.6) 0.434* 
Laboratory Values 
      
 
WBC 5.5 (± 1.6) 8.5 (± 3.3) 13.6 (± 11.4) 15.8 (± 4.3) 15.1 (± 9.0) 21.7 (± 19.9) 0.002 
Platelets 199 (± 65) 152 (± 62) 117 (± 105) 198 (± 83) 113 (± 76) 92 (± 71) 0.004 
Protime 
 
31.0 (± 14.4) 29.1 (± 15.8) 22.8 (± 9.2) 24.5 (± 11.7) 35.7 (± 23.9) 0.130 
INR 0.9 (± 0.5) 3.2 (± 1.7) 2.9 (± 1.8) 2.3 (± 1.2) 2.3 (± 1.2) 4.1 (± 2.9) 0.027 
Bilirubin 0.4 (± 0.2) 15.6 (± 11.0) 13.0 (± 9.9) 13.5 (± 11.0) 14.5 (± 12.0) 13.9 (± 9.4) 0.919 
AST 
 
2231 (± 4190) 1745 (± 3664) 692 (± 1278) 938 (± 1497) 4382 (± 4390) 0.017 
ALT 
 
2976 (± 3090) 2270 (± 4698) 1030 (± 718) 1125 (± 1532) 2145 (± 3286) 0.155 
Creatinine 0.9 (± 0.1) 1.8 (± 1.6) 2.6 (± 2.0) 1.1 (± 0.28) 2.4 (± 1.8) 3.1 (± 1.1) 0.007 
Lactate 
 
8.6 (± 17.4) 8.8 (± 7.7) 
 
21.0 (± 36.4) 27.1 (± 40.8) 0.283 
pO2 
 
140 (± 72) 97 (± 31) 145 (± 87) 113 (± 37) 99 (± 40) 0.017 
O2 sat 
 
98 (± 2) 93 (± 16) 96 (± 5) 98 (± 2) 92 (± 12) 0.167 
pCO2 
 
33.7 (± 4.0) 27.8 (± 7.1) 27.6 (± 1.4) 26.6 (± 6.1) 25.1 (± 5.4) <0.001 
FiO2 
 
38.6 (± 27.3) 37.8 (± 21.9) 32.4 (± 15.6) 41.5 (± 23.4) 58.4 (± 33.3) 0.065 
pO2 / FiO2 
 
422 (± 200) 277 (± 149) 456 (± 159) 270 (± 113) 287 (± 372) 0.399 
*Septic Shock was not included because the MAP level is defined by the category 
 
the analysis because the MAP values were inclusion/exclusion criteria for the category.  
Parameters from the laboratory data that were significantly different included WBC (p-
value = 0.002), platelet (p-value = 0.004), INR (p-value = 0.027), AST (p-value = 0.017), 
creatinine (p-value = 0.007), pO2 (p-value = 0.017), and pCO2 (p-value < 0.001). 
Statistical Results 
 Because the PCT values were not normally distributed, the PCT values were 
transformed using the following equation:  Log10 (PCT + 1). The horizontal line in Figure 
5 represents the 2.0 ng/mL cut-off that is indicative of severe sepsis in the literature 
(Harbarth et al., 2001). As can be seen, the distribution of SPCTC results of the different 
severity categories vary greatly. Because the assumption of equal variances among  
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Figure 5: SPCTC by SIRS Classifications 
This graph represents the median transformed SPCTC values for the six patient severity groups. The 
horizontal line represents the transformed 2.0 ng/mL SPCTC cutoff value indicative of severe sepsis. 
 
groups for an ANOVA was violated, the non-parametric Kruskal-Wallis test was used to 
address the following hypotheses for Specific Aim 1. 
H0:  There is no difference in SPCTCs between non-infected ALF/ALI patients 
and non-infected chronic liver disease patients. 
 The Kruskal-Wallis test indicated a significant difference between the three non-
infection groups (chronic, Neg SIRS, and SIRS) with a 2 = 43.682 (df = 2, p-value 
<0.001). Using the post hoc multiple comparisons tests with the Dunn Method  (Elliot & 
Hynan, 2011), there is a significant difference between the chronic group and the Neg 
SIRS (p-value <0.001) and the SIRS (p-value <0.001) groups. However, there was no 
significant difference between the Neg SIRS and SIRS categories (p-value >0.05).  
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 The next hypothesis addressed the comparison of non-infected subjects to the 
SPCTC reference value: 
H0:  There is no difference in SPCTSs between non-infected patients with liver 
disease (chronic and ALF/ALI) and the published SPCTC reference range (<0.1 
ng/mL) for non-infected patients in the general population. 
For this hypothesis, a one sided t-test was used to determine if there were differences 
between the SPCTC results for all non-infected patients and the documented reference 
range (<0.1 ng/mL) for non-infection. When all of the non-infected patients (chronic, 
Neg SIRS, and SIRS) were tested, the mean transformed SPCTC (tSPCTC) value was 
0.393 (SPCTC = 1.472 ng/mL). This mean was significantly different from the null 
hypothesis value of 0.1 (based upon the package insert reference range value for non-
infected patients in the general population of <0.1 ng/mL) with a t value of 8.741 (df = 
79, p-value <0.001). When the single outlier in the chronic patients group was removed 
from the data and the analysis was repeated, the p-value was still <0.001. However, when 
each category was analyzed individually, the results for patients with chronic liver 
disease were not significantly different from the published reference range, while results 
from each of the other two categories (Neg SIRS and SIRS) were significantly different 
(Table 14). 
 The final Specific Aim 1 hypothesis addressed the comparison of the five severity 
categories: 
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Table 14:  Comparison of tSPCTC in Non-Infected Patients to the Published Reference 
Value (<0.1 ng/mL) 
 
Category Mean 
(ng/mL) 
SD df t statistic 1-sided 
p-value 
All 0.393 0.357 78 8.741 <0.001 
Chronic 0.043 0.017 19 0.511 0.307 
Neg SIRS 0.510 0.327 29 7.854 <0.001 
SIRS 0.512 0.358 28 7.089 <0.001 
 
H0:  There is no difference in SPCTC between ALF/ALI patients with different 
degrees of severity of infection (i.e., no infection, SIRS, sepsis, severe sepsis, and 
septic shock). 
Kruskal-Wallis with post hoc testing (Dunn Method) was used to evaluate the five ALF 
patient categories. The Kruskal-Wallis test showed that overall there was a significant 
difference in SPCTC among the five categories (2 = 15.583, df = 4, p-value = 0.003). 
However, in Table 15, the mean ranks of each of the five categories indicate that the 
significant differences were found only between the sepsis category and the severe sepsis 
(p-value <0.01) and septic shock categories (p-value <0.05). 
Table 15:  Results for post hoc Pairwise Testing Using the Dunn Method 
 
Category N Mean Rank p-value 
No. Name vs 2 vs 3 vs 4 vs 5 
1 Neg SIRS 30 53.60 >0.05 >0.05 >0.05 >0.05 
2 SIRS 29 51.83  >0.05 >0.05 >0.05 
3 Sepsis 13 34.62   <0.01 <0.05 
4 Severe Sepsis 27 71.63    >0.05 
5 Septic Shock 16   73.44     
 
 Subjects in the sepsis, severe sepsis, and septic shock groups were examined 
based upon types of cultures:  blood cultures vs. all other culture types. A 2-way analysis 
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of variance was performed to examine the difference in SPCTC by type of culture (blood 
vs. all other culture types), severity categories (sepsis, severe sepsis, and septic shock), 
and the interaction of these two factors. The interaction between the type of culture and 
severity categories (F = 0.098, dfn = 1, dfd = 50, p-value = 0.906) and the type of culture 
category (F = 1.419, dfn = 1, dfd = 50, p-value = 0.239) were non-significant. However, 
there was a significant difference between the severity categories (F = 3.627, dfn = 2, dfd 
= 50, p-value = 0.034). While there was a difference between the transformed means for 
severity, there is no difference between the SPCTC levels for subjects with positive blood 
cultures and positive non-blood cultures.  
 Because the sepsis category did not, by definition exist in the ALF population, 
SPCTC results were examined with the sepsis severity category combined with the severe 
sepsis severity category. When the SPCTC results were examined without the sepsis 
severity category, there were no significant differences between the categories (2 = 
5.038, df = 3, p-value = 0.169). 
 The Neg SIRS and SIRS categories that were presumed to have no infection 
demonstrated mean SPCTCs at or above the 2.0 ng/mL cut-off and while the Sepsis 
category which had documented infections had a mean SPCTC that was below the 2.0 
ng/mL cut-off. For this reason, there was still some uncertainty as to the actual cut-off 
value denoting the presence of infection was for this population. To address this, the 
SPCTC data from all categories were re-categorized based upon infection and non-
infection and a ROC analysis was performed. Samples were entered into the analysis 
listwise and the coordinates of the ROC curve were generated based upon sensitivity and 
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1-specificity at each value for SPCTC (Figure 6). The sensitivity indicates the percentage 
of samples correctly identified as infected when they are actually infected. The specificity 
is the percentage of samples correctly identified as not infected when they do not have an 
infection. The tests results for the ROC produced an area under the curve (AUC) equal to 
0.697 (SE = 0.044, p-value <0.001). Upon examining the results of the coordinates of the 
curve, it was determined that the best cut-off value for this set of data, using a 
combination of criteria, was 1.62:  1) the point on the curve that was at the greatest 
distance (0.186) from the 0.5 reference line at a 45
O
 angle to the line, 2) accuracy, 3) 
sensitivity (0.643), 4) specificity (0.620), and 5) likelihood ratio (1.693).  
   
 
Figure 6:  Receiver Operator Curve for the Detection of Infection in ALF and ALI 
patients Using SPCTC 
The ROC analysis resulted in an AUC of 0.697 with a sensitivity of 64.3% and a specificity of 62.0% for 
the use of PCT in the detection of infection this population of ALF and ALI patients.  
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When the biodata between the ALF subjects with a SPCTC, that was less than the 
1.62 ng/mL cut-off and those with a SPCTC that was greater than or equal to the cut-off 
are compared, with the exception of creatinine, AST, ALT, and bilirubin, all biodata 
parameters had similar results (Table 16). It is uncertain how the differences in these 
laboratory results impacted the SPCTC values, but they were noted. However, there are 
several features of note about the > 1.62 ng/mL group. First, 52.2% of the subjects in the 
> 1.62 ng/mL group had a diagnosis of acetaminophen toxicity, which was 84.5% of all 
APAPs in the study. This raised a question as to whether APAP toxicity and the resulting 
liver damage it caused was a factor in the increased SPCTC. In addition, the majority 
(65.0%) of subjects in the Neg SIRS and SIRS categories had an outcome of death or 
received a liver transplant. This will be discussed more fully later, in the discussion of 
Specific Aim Three. 
 Fifty percent of all ALF cases in the ALFSG database are a result of APAP 
toxicity. To ensure an equal distribution of etiology types in this section of the study, 
equal numbers of samples were requested for each of three etiology types:  
acetaminophen toxicity, viral hepatitis, and all other etiologies. An interesting trend was 
noted when SPCTC results were examined based upon etiology. The SPCTC median 
values for subjects with APAP toxicity were higher than the other etiologies in all of the 
severity categories (Figure 7). The median SPCTC results for the severity categories with 
APAP etiology were 3.0 to 6.6 times higher than the results for the respective severity 
categories for all other etiologies (Table 17), again suggesting that patients with APAP 
toxicity may have elevated SPCTC values unrelated to infection. However, the patterns  
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Table 16:  Demographic and Biodata Results Based Upon the Calculated Infection Cut-
off Value of 1.62 ng/mL 
 
Mean (± SD) or  
Number (%) 
SPCTCs > 1.62 ng/mL 
n = 67 
SPCTCs < 1.62 ng/mL 
n = 48 
p-value 
ALF Etiology    
APAP 35 (52.2) 6 (12.5)  
Viral hepatitis 11 (16.4) 17 (35.4)  
Other 21 (31.3) 25 (52.1)  
Outcome (TFS)    
APAP 21(31.3) 3 (6.2)  
Viral Hepatitis 3 (4.5) 5 (10.4)  
Other 6 (9.0) 5 (10.4)  
WBC 13.7 (+ 9.7) 14.4 (+ 12.9) 0.732 
Platelet 120 (+ 91) 146 (+ 76) 0.104 
INR 2.8 (+ 1.7) 3.1 (+ 2.1) 0.409 
Glucose 149.0 (+ 97.7) 121.2 (+ 43.3) 0.215 
Creatinine 2.8 (+ 1.9) 1.4 (+ 0.8) 0.000 
AST 2828 (+ 4142) 739 (+ 1862) 0.001 
ALT 2870 (+ 3873) 1179 (+ 1925) 0.006 
Lactate 17.4 (+ 30.2) 7.2 (+ 7.5) 0.222 
Bilirubin 10.4 (+ 9.9) 19.2 (+ 9.7) 0.000 
pO2 111.3 (+ 41.9) 120.3 (+ 68.5) 0.428 
pCO2 27.7 (+ 7.1) 28.8 (+ 4.8) 0.388 
Pulse 51 (+ 49) 68 (+ 45) 0.108 
Respiration 11 (+ 10) 14 (+ 9) 0.204 
Min Temp 36.6 (+ 1.2) 36.5 (+ 0.9) 0.663 
Max Temp 37.2 (+ 1.3)  36.9 (+ 0.8) 0.303 
Coma Grade    
0 / Not reported 4 3  
1 9 7  
2 9 11  
3 12 9  
4 33 18  
Means were calculated based upon the available data  
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Figure 7: Median SPCTCs by SIRS Categories Sorted by Etiologies                                   . 
This graph represents the median transformed SPCTC values for the five patient severity groups sorted by 
etiologies: APAP and All Others etiologies (combined viral and other). 
 
Table 17: Comparison of Median SPCTC Results of Subjects in Specific Aim One Sorted 
by Category and Etiologies 
 
 
Neg SIRS SIRS Sepsis Severe Sepsis Septic Shock 
N 
Median 
(ng/mL) N 
Median 
(ng/mL) N 
Median 
(ng/mL) N 
Median 
(ng/mL) N 
Median 
(ng/mL) 
All Etiologies 30 1.57 30 2.29 13 0.69 26 3.46 16 5.89 
APAP  10 4.53 10 3.38 6 1.48 10 11.34 5 11.37 
All Other Etiologies 20 1.05 20 1.07 7 0.50 16 2.41 11 1.71 
  
of the results for the APAP and All Other Etiologies groups remain same as the overall 
data:  SPCTC results in the Neg SIRS and SIRS severity categories were higher than 
those of the sepsis category, while the Severe Sepsis and Septic Shock categories had the 
SPCTC highest levels. When Kruskal-Wallis statistical analyses were performed on the 
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two etiology groups (APAP vs. all other etiologies), there were significant differences 
among the severity categories for the All Other Etiologies group with a 2 = 12.942 (df = 
4, p-value = 0.012). However, there were no significant differences among the severity 
categories for the APAP etiology group with a 2 = 8.515 (df = 4, p-value = 0.074). The 
patterns of the mean ranks for each subgroup were similar to the pattern of the mean 
ranks for all subjects (Figure 8). 
 
 
Figure 8: Comparison of Kruskal-Wallis Mean Ranks for All, APAP, and Other 
Etiologies                                                                                                                               ,                       
The patterns of the mean ranks of the APAP and Other Etiologies across the five categories were similar to 
the pattern for all subjects. The levels of the three etiology groupings are different due to the differing 
number of subjects in each grouping. 
 
 A ROC analysis was performed on non-APAP subjects only, the AUC was 0.612 
(SE = 0.066, p-value = 0.099). Upon examining the results of the coordinates of the 
curve, it was determined that the best cut-off value for the non-APAP data was 1.62, with 
a sensitivity of 0.543 and a specificity of 0.692. 
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Specific Aim Two 
 The purpose of Specific Aim 2 was to determine the utility of SPCTC as a 
screening biomarker for infection in ALF patients. To accomplish this, subjects with a 
confirmed infection and with samples available on the day of infection and the three days 
prior to the day of infection were tested to determine the SPCTC values. Results were 
analyzed to determine if SPCTC results increased relative to the day of infection and on 
which day – DoI, Day -1, Day -2 or Day -3. 
Sample Selection 
 From the 1863 patients that were available from the ALF and ALI databases, 130 
subjects had an infection identified on Days 4, 5, 6, or 7 without a confirmed infection on 
the prior days. A list of these subjects was given to the Program Manager to randomly 
select 45 subjects who had samples available for each of the four days required for this 
portion of the study (DoI and 1, 2, and 3 days prior to DoI). A total of 34 subjects met 
these criteria.  
Demographic Information 
 These subjects had a mean age of 40.2 years (SD = 13.9, median = 41.0, range 18 
to 73), were 61.8% female, and 88.2% Caucasian.  The proportion of etiologies 
represented (APAP = 44.1%, viral hepatitis = 8.8%, and all other etiologies = 47.1%) 
were similar to that described by the USALFSG overall for the ALF and ALI studies 
(APAP – 50%, viral hepatitis – 12%, and all other causes 38%) (Lee & Seremba, 2008; 
United States Acute Liver Failure Study Group, 2011). The types of cultures that were 
positive for bacterial growth were equally distributed between blood (35.3%), tracheal 
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aspirates (29.4), and urine (32.3%) cultures. There was a single positive catheter culture 
(2.9%). Within the blood and tracheal aspirate cultures, seven subjects had multiple 
positive culture sites on the DoI (20.5% of total). Table 18 provides the demographic 
information for the patients included in the analysis for Specific Aim Two. 
Statistical Results 
 When all SPCTC values for each subject (Days -3, -2, -1, and DoI) were plotted, 
the concentrations vary greatly across all days (Figure 9). There is no readily apparent 
overall trend to the values. The median values for all days are in fact very similar, as can 
be seen from the box plots in Figure 10. A Friedman test for non-parametric related 
samples was used to test the hypothesis for this part of the study. 
H0:  There is no difference in SPCTC in ALF/ALI patients between the first day a 
positive culture was collected and the three days prior to a positive culture. 
The results of the analysis gave a 2 = 6.741 (n = 34, df = 3, p-value = 0.081) indicating 
no significant difference in the PCT concentrations for the four days.  
 Because there appeared to be some patterns within the samples, the samples were 
sorted based upon the Day -3 (D-3) and DoI serum PCT concentrations.  
 Subgroup A – D-3 samples were greater than the 3.0 ng/mL  
 Subgroup B – D-3 samples were  less than 3.0 ng/mL and had an increase by DoI 
 Subgroup C – D-3 samples were at or below the 1.62 ng/mL cutoff and SPCTC 
values remained below the 1.62 ng/mL cut-off or decreased by DoI 
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Table 18:  Demographic Information for 34 Patients Analyzed for SPCTC to Detect 
Bacterial Infection 
 
Mean (± SD) or Number (%) n = 34 
Gender  
Female 21 (61.8) 
Male 13 (38.2) 
Race / Ethnicity  
Hispanic 4 (11.8) 
Caucasian 30 (88.2) 
African-American 1 (2.9) 
Asian 1 (2.9) 
Native American 2 (5.9) 
Age (years) 40.2 (± 13.9) 
Sample age (years) 8.3 (± 2.7) 
Days In Hospital Prior DoI 8.0 (± 5.0) 
Etiologies  
Acetaminophen 15 (44.1) 
Viral Hepatitis 3 (8.8) 
All others 16 (47.1) 
Outcomes (TFS)  
Acetaminophen 11 (32.4) 
Viral Hepatitis 0 (0.0) 
All others 7 (20.6) 
Culture types  
Blood culture -1 6 (17.6) 
Tracheal aspirates - 2 9 (26.5) 
Urine - 3  11 (32.4) 
Catheter - 5 1 (2.9) 
*Multiple w Blood – 7 6 (17.6) 
**Multiple wo Blood – 8 1 (2.9) 
Antibiotic  
Prophylaxis  11 (32.4) 
Antibiotic Therapy 20 (58.8) 
Antibiotics Used 25 (73.5) 
Coma Grade (DoI)  
Not Reported/0 8 (23.5) 
1 6 (17.6) 
2 6 (17.6) 
3 4 (11.8) 
4 10 (29.4) 
*Blood culture in combination with other culture types 
** Multiple culture types in combinations that do not include blood cultures 
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Figure 9:  SPCTC Results for All Subjects for Three Days Prior to and the Day of 
Infection  
Each series of results represents one subject’s SPCTC results for Day of Infection (DoI), one Day prior to 
DoI (D-1), two Days Prior to DoI (D-2), and three Days prior to DoI (D-3). 
 
 
 
Figure 10:  SPCTC Values for DoI and Three Days Prior to DoI 
The lines within the box represent the medians for the transformed SPCTC values for the Day of Infection 
(DoI) and three days prior to DoI.  
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The 3.0 ng/mL break between Groups A and B was chosen because it was centralized in 
a nearly 1.0 ng/mL gap between the lowest Group A sample (3.48 ng/mL) and the highest 
Group B sample (2.65 ng/mL) when the D-3 SPCTC values were placed in rank order. 
Rank ordered D-3 SPCTC values for Groups B and C were intermixed. To help sort these 
groups SPCTC values for the DOI were examined and values that increased were 
assigned to Group B and those values that remained below the 1.62 ng/mL cut-off were 
assigned to Group C.   
 In Subgroup A (Figure 11), all of the SPCTCs on D-3 were above 5.0 ng/mL with 
the exception of one sample that was 3.95 ng/mL. All subjects showed a general decrease 
in SPCTC by DoI. 
 
 
 
Figure 11:  SPCTC Results for Subjects in Subgroup A  
Subjects SPCTC results in Subgroup A were all greater than 3.0 ng/mL on D3 prior to Day of Infection.  
The majority showed a decrease in the SPCTC by DoI. 
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 Subgroup B (Figure 12) had SPCTCs on D-3 that were <3.0 ng/mL and increased 
by DoI. While the SPCTC values for some subjects initially decreased, all subjects had 
SPCTC values that increase above the 3 ng/mL D-3 level on or before the DoI.  
 
 
Figure 12:  SPCTC Results for Subjects in Subgroup B 
Subjects SPCTC results in Subgroup B were all less than 3.0 ng/mL on D3 prior to Day of Infection.  All 
SPCTC results increased by DoI to values greater than 3 ng/mL. 
  
 Subgroup C (Figure 13) had SPCTCs on D3 that were less than or equal to the 
1.62 ng/mL cutoff with the exception of one subject that had a D-3 SPCTC of 1.84 
ng/mL. All subjects’ SPCTC results were less than 1.0 ng/mL by DoI.  
 There were no apparent differences in the demographic characteristics among 
three subgroups and all subjects on the DoI with the exception of Subgroup B, which had 
an increased WBC. Other variables such as lactate, pCO2, pulse, respiration, and  
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Figure 13:  SPCTC Results for Subjects in Subgroup C 
Subjects SPCTC results in Subgroup C were all less than the 1.62 ng/mL cut-off on D3 prior to Day of 
Infection.  The SPCTC results remained below the 1.62 ng/mL cut-off or decreased by DoI.  
   
temperature were not calculated because in most cases there were a large number of 
missing values (Table 19).  
A Friedman Test was used on each of the subsets of subjects to determine if there 
were any significant differences in the SPCTC results among each of the four days tested 
(Table 20). The subjects from Subgroup A showed a significant change between days 
with a 2 = 18.257 (df = 3, p-value <0.001). These patients had a decrease in the median 
SPCTC values from 7.16 ng/dL on D-3 to 3.40 ng/dL on DoI for an overall decrease in 
the mean SPCTC values of 52.5%. Using a Wilcoxon Signed Ranks test, the change 
between D-3 and DoI was significant (p-value 0.013, Z = -2.480). The differences 
between Day -2 (D-2) and Day -1 (D-1) and the DoI were not significant (D-2 p-values = 
0.74, D-1 p-value = 0.096). While two (14.3%) of the subjects in this group did not 
receive antibiotics (prophylaxis or therapy), four (28.6 %) received prophylactic  
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Table 19:  Demographic Data for All Subjects and Each of the Three Subgroups on the 
Day of Infection 
 
Mean (± SD) or 
Number (%) 
All Subgroup A Subgroup B Subgroup C 
n = 34 n = 14 n = 8 n = 12 
Days in Hospital  
Prior to D-3 
Mean = 3.18 
Median = 2 
Mean = 4.14 
Median = 2 
Mean = 2.13 
Median = 1 
Mean = 2.75 
Median = 2 
Etiologies     
Acetaminophen 15 (44.1) 10 (71.4%) 2 (25.0) 3 (25.0) 
Viral Hepatitis 3 (8.8)  1 (12.5) 2 (16.7) 
Other 16 (47.1) 4 (28.6%) 5 (62.5) 7 (58.3) 
Outcome (TFS)     
APAP 11 (32.4) 9 (64.3) 1 (12.5) 1 (8.3) 
Viral Hepatitis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Other 7 (20.6) 3 (21.4) 2 (25.0) 2 (16.7) 
WBC 13.8 (± 11.4) 12.7 (± 6.6) 20.2 (± 20.0) 10.6 (± 5.5) 
Platelet 85 (± 58) 98 (± 66) 66 (± 37) 114 (± 55) 
INR 2.2 (± 1.4) 1.7 (± 0.6) 1.8 (± 0.5) 3.0 (± 2.0) 
Bilirubin 14.9 (± 9.8) 13.1 (± 8.1) 15.4 (± 11.7) 16.9 (± 10.8) 
AST 352 (± 378) 245 (± 207) 380 (± 467) 486 (± 474) 
ALT 687 (± 630) 858 (± 709) 430 (± 475) 668 (± 613) 
Creatinine 2.3 (± 2.0) 2.9 (± 2.0) 3.2 (± 2.6) 0.9 (± 0.5) 
Coma Grade     
0 / Not reported 8 (23.5) 4 (28.6) 2 (25.0) 2 (16.7) 
1 6 (17.6) 2 (14.3) 2 (25.0) 2 (16.7) 
2 6 (17.6) 3 (21.4) 1 (12.5) 2 (16.7) 
3 4 (11.8) 1 (7.1) 1 (12.5) 2 (16.7) 
4  10 (29.4) 4 (28.6) 2 (25.0) 4 (33.3) 
Antibiotics     
Used 25 (73.5) 12 (85.7) 4 (50.0) 9 (75.0) 
Prophylaxis 11 (32.4) 4 (28.6)   3 (37.2) 4 (33.3) 
Treatment 20 (58.8) 10 (71.4) 4 (50.0) 6 (50.0) 
Culture types     
Blood culture -1 6 (17.6) 1 (7.1) 3 (37.5) 2 (16.7) 
Tracheal aspirates - 2 9 (26.5) 4 (28.6) 3 (37.5) 2 (16.7) 
Urine - 3  11 (32.4) 5 (35.7) 1 (12.5) 5 (41.7) 
Catheter - 5 1 (2.9) 1 (7.1)   
*Multiple w Blood – 7 6 (17.6) 3 (21.4) 1 (12.5) 2 (16.7) 
**Multiple wo Blood – 8 1 (2.9)   1 (8.3) 
*Blood culture in combination with other culture types 
** Multiple culture types in combinations that do not include blood cultures 
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Table 20:  Friedman Test for SPCTC Results for All Samples and Subgroups A, B, and C 
 
Median 
Mean Rank N D-3 D-2 D-1 DoI 
Chi-
Square df p-value 
All samples 34 2.04 
2.91 
2.11 
2.62 
1.16 
2.18 
2.37 
2.29 
6.741 3 0.081 
Subset A 14 7.16 
3.50 
5.28 
2.86 
4.78 
2.07 
3.40 
1.57 
18.257 3 <0.001 
Subset B 8 1.96 
2.13 
1.99 
2.00 
2.09 
2.13 
5.34 
3.75 
10.050 3 0.018 
Subset C 12 0.44 
2.75 
0.47 
2.75 
0.40 
2.33 
0.39 
2.17 
1.900 3 0.593 
  
antibiotics and twelve (85.7 %) received antibiotics (therapy or prophylaxis). The two 
subjects who did not receive antibiotics had the highest and the lowest values for all days 
in this group and had documented urinary tract infections on DoI. Also of interest in this 
group is the large number of APAP cases. It was noted earlier, the SPCTC results of 
APAP cases appeared to have increased levels compared to the SPCTC levels for the 
other etiologies. This may be influencing the results in this subgroup irrespective of any 
evidence of infection. 
 Patients from Subgroup B also showed a significant change in the SPCTC values 
between days. The median SPCTC values increased from 1.96 ng/mL on D-3, 1.99 
ng/mL on D-2, 2.09 ng/mL on D-1 to 5.34 ng/mL on DoI. The Freidman test gives a  
2 = 10.050 (df = 3, p-value = 0.018). The Wilcoxon Signed Ranks test showed 
significant differences between DoI and both D-3 and D-2 (Z = -2.380, p-value = 0.017 
and Z = -2.521, p-value = 0.012, respectively). No other pairs were significant.  
 Patients from Subgroup C had median SPCTC values for all days that were below 
the 1.62 ng/mL cutoff. In fact there were only two values from the whole group (n = 12) 
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that were at or above the cutoff on D-3 but decreased below the cutoff by D-2 and 
remained there. Both patients had confirmed bacterial positive cultures on tracheal 
aspirates (one also had a positive blood culture) and both received antibiotics. There were 
12 subjects in C group of which 75% received antibiotics (prophylaxis or therapy). Urine 
cultures accounted for 41.7% of the positive bacterial cultures followed by 33.4% blood 
cultures and 25.0% tracheal aspirate cultures.  
Specific Aim Three 
 The purpose of Specific Aim 3 was to determine if changes in the SPCTC in ALF 
and ALI patients, with a confirmed bacterial infection on Day 1, would predict which of 
two outcomes these patients would achieve – 1) transplant free survival or 2) death or 
transplant.  
Sample Selection 
 Of the 1863 available ALF and ALI subjects, 259 subjects had a documented 
positive culture on Day 1, of which 207 had a positive culture on day 1 only. The 52 
subjects with cultures on multiple days were eliminated to avoid a potentially 
confounding variable. The sample list was sorted by outcome (TFS or DoT) and the list 
was given to the Project Manager.  Samples from 30 subjects from both outcome groups, 
TFS and DoT, with serum samples for each of the seven days of the ALF or ALI studies 
were requested. It was determined that there were too few subjects in either group with 
all seven samples available. There are several reasons that samples might be missing that 
included: 
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 Subjects no longer enrolled in the study due to death, transplant, discharge, or 
withdrawal of consent 
 ALF and ALI studies are a non-treatment study that collects clinical data and 
samples if available 
 Sample aliquot inventory from individual days may have been depleted and 
therefore unavailable 
The requirements were adjusted to include subjects based upon the following minimum 
requirements for each subject: 
 Days 1 – 4 samples were available 
 Single days could be missing if more than 5 days were available   
 Missing days could not be Day 1 or any consecutive days (except at the end of the 
series) 
The final available sample sets were 26 subjects for the TFS group and 21 subjects for the 
DoT group. Table 21 shows the number of available results for each group by day. As 
can be seen, the number of available samples decreases on Days 5, 6, and 7 for both 
groups but the decrease is greater in the DoT group.  
Table 21:  Number of Samples Tested by Days and Outcomes 
 N Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day7 
TFS 26 26 
(100%) 
26 
(100%) 
25 
(96.2%) 
23 
(88.5%) 
22 
(84.6%) 
18 
(69.2%) 
16 
(61.5%) 
DoT 21 21 
(100%) 
20 
(95.2%) 
20 
(95.2%) 
21 
(100%) 
13 
(61.9%) 
9 
(42.9%) 
6 
(28.6%) 
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Demographic Information 
 Demographic information for both groups (TFS and DoT) is described in Table 
22. Both groups were similar in all characteristics described except the etiology of ALF.  
The TFS group had a higher percentage of APAP subjects (73.1%) compared to DoT 
group (19.0%), while the DoT group had a higher percentage of Other etiologies (76.2%) 
compared to APAP (23.1%). 
 A comparison of the laboratory values for TFS and DoT on DoI (see Table 23) 
indicated that except for bilirubin and lactate (which are higher in the DoT group) the two 
groups were similar.  
Statistical Results 
 The SPCTC values ranged from 0.13 ng/mL to 103.75 ng/mL. Because of the 
non-normally distributed SPCTC results and the large number of missing samples, a 
mixed models analysis of covariance was used to test the longitudinal hypotheses. This 
model has two assumptions regarding the sample data: 1) the sample results are normally 
distributed and have equal variances and 2) the missing data are randomly missing. 
Because the SPCTC results were widely distributed, the SPCTC values were transformed 
using the following formula:  Log10 (SPCTC +1) = transformed SPCTC (tSPCTC) to 
address the first assumption. One was added to the SPCTC so that SPCTC results 
transformed using Log10 would normalize the variances without introducing negative 
numbers into the data set. Figure 14 shows the box plot representation of both categories 
of tSPCTCs for all seven days. Days five, six, and seven had the largest number of 
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 Table 22:  Demographic Information Based on Outcomes for Patients with a 
Documented Infection on Day of Admission to the ALF or ALI Studies 
 
Mean (± SD) or No. (%) TFS (n = 26) DoT (n = 21) 
Gender   
Female 20 (76.9) 16 (76.2) 
Male 6 (23.1) 5 (23.8) 
Race / Ethnicity   
Hispanic 0 2 (9.5) 
Caucasian 23 (88.5) 16 (76.2) 
African-American 2 (7.7) 3 (14.3) 
Native American 0 1 (4.8) 
Native Hawaiian / Pacific Islander 1 (3.8) 0 
Other 0 1 (4.8) 
Age (years) 40.6 (± 14.5) 44.8 (± 13.9) 
Sample age (years) 6.5 (± 2.9) 7.4 (± 2.6) 
Days In Hospital Prior DoI 2.5 (± 2.0) 5.6 (± 10.0) 
Etiologies   
Acetaminophen 19 (73.1) 4 (19.0) 
Viral Hepatitis 1 (3.8) 1 (4.8) 
All others 6 (23.1) 16 (76.2) 
Culture types   
Blood culture - 1 4 (15.4) 4 (19.0) 
Tracheal aspirates - 2 5  (19.2) 4 (19.0) 
Urine – 3 9 (34.6) 7 (33.3) 
Ascites - 6 1 (3.8) 1 (4.8) 
*Multiple w Blood – 7 3 (11.5) 4 (19.0) 
**Multiple wo Blood – 8 4 (15.4) 1 (4.8) 
Antibiotic   
Antibiotics Used 18 (69.2) 18 (85.7) 
Prophylaxis  8 (30.8) 12 (57.1) 
Antibiotic Therapy 15 (57.7) 14 (66.7) 
Coma Grade ***   
1 6 (23.1) 3 (14.3) 
2 7 (26.9) 6 (28.6) 
3 6 (23.1) 5 (23.8) 
4 7 (26.9) 7 (33.3) 
*Blood culture in combination with other culture types 
** Multiple culture types in combinations that do not include blood cultures  
***Based on Day 1 Coma Grade 
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Table 23:  Laboratory Values for Patients with a Documented Infection on the  
Day of Admission to the ALF or ALI Studies 
Mean (± SD)  TFS (n = 26) DoT (n = 21) p-value 
WBC 8.5 (± 3.8) 14.4 (± 15.1) 0.060 
Platelet 148 (± 95) 183 (± 132) 0.300 
INR 3.5 (± 3.4) 2.9 (± 1.8) 0.410 
Bilirubin 7.4 (± 6.6) 18.0 (± 11.8) <0.001 
AST 3718 (± 4833) 2876 (± 4657) 0.549 
ALT 2876 (± 2821) 2392 (± 3763) 0.616 
Glucose 132 (± 50) 112 (± 46) 0.183 
Creatinine 1.6 (± 1.3) 2.4 (± 1.4) 0.058 
Lactate 2.9 (± 2.0) 6.3 (± 4.5) 0.017 
pCO2 31 (± 7) 29 (± 10) 0.367 
Pulse 101 (± 30) 101 (± 24) 0.964 
Respiration 21 (± 7) 20 (± 7) 0.623 
Min Temperature 35.5 (± 7.3) 37.0 (± 0.9) 0.373 
Max Temperature 35.8 (± 7.4) 37.1 (± 1.1) 0.420 
 
 
 
Figure 14:  Median tSPCTC per Day Sorted by Outcome 
This graph represents the median transformed SPCTC results for Days 1 - 7 for the TFS (blue) and ToD 
(green) outcome groups.  
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missing samples (see Table 21). Six of 47 subjects had samples missing prior to their last 
day in the study. All other missing samples were after Day 4. The mixed effects model 
controls for Type 1 error better than other models when the missing samples rates are 
different for each group, and the missing samples can be attributed to the outcome 
(Mallinckrodt, Kaiser, Watkin, Molenberghs, & Carroll, 2004). In this case, the DoT 
group was missing more samples than the TFS group on days five, six, and seven in large 
part due to the subjects’ death or discontinuation from the study because they received a 
liver transplant. The mixed model was used to test the hypotheses: 
H0:  There is no difference in SPCTC between ALF/ALI patients with a bacterial 
infection/sepsis who have transplant free survival and those who die or receive a 
liver transplant. 
H0:  There is no difference in changes in the serial SPCTCs between ALF/ALI 
patients with a bacterial infection/sepsis who have transplant free survival and 
those who die or receive a liver transplant. 
 There appeared to be little difference between the SPCTC results for the TFS 
subjects and the DoT subjects when the transformed data was examined (Figure 14). 
However, the TFS group had a larger and faster decrease in the median SPCTC results 
than the DoT group. The TFS group had a decrease of 66.6% during Days 1 – 5 with an 
overall decrease by Day 7 of 70.3%.  The DoT group that had a 43.7% increase in the 
median SPCTC values by Day 4 after which the values began falling. The overall 
decrease in the median SPCTC values for the DoT group (Days 1 through 7) was 49.3% 
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(Table 24). However, it should be noted that by Day 7 there were only 6 of 21 subjects 
available for analysis in the DoT group compared to 16 of 26 in the TFS group. 
Table 24:  Change in Medians of SPCTC From Day 1 in TFS and DoT Subjects 
 Medians 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
TFS 2.90 2.18 1.49 1.07 0.97 1.12 0.86 
Change per day (%)  24.8 31.7 28.2 9.3 -15.5 23.2 
DoT 1.42 1.30 2.03 2.04 1.9 0.82 0.72 
Change per day (%)  8.5 -56.2 -0.5 6.9 56.8 12.2 
 
 To examine differences in the two outcome groups in the longitudinal 
measurement of SPCTC we considered the following factors:  outcome (TFS vs. DoT), 
visit day, diagnosis (APAP vs. Other Etiologies), severity of illness (sepsis, severe sepsis, 
and septic shock), use of antibiotics (prophylaxis and/or therapy), antibiotic prophylaxis, 
antibiotic therapy, coma grade (1-2, mild vs. 3-4, severe), and interactions of these 
factors.  Additional analyses examined those with positive blood cultures (n = 15) 
however, the number of cases was too small to adequately model the data. The final 
mixed models analysis of covariance with 1-repeated measure (visit days 2, 3, 4, 5, 6, and 
7), 2-between groups (outcome and antibiotic use), interaction of outcome * visit day, 
and baseline SPCTC as a covariate were fit to the data. Baseline covariate of Day 1 
SPCTC values was significant (p<0.0001). The interaction of outcome * visit day was 
significant (p-value = 0.0403). After accounting for the baseline covariate, the least 
square mean estimates for the interaction (Figure 15) show that while the values on Day 2 
are similar, the tSPCTC values fell faster in the TFS group than the tSPCTC values in the 
DoT group. Overall, the TFS SPCTC values were lower than the DoT SPCTC values (p-  
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Figure 15:  Estimates of Visit Day * Outcome by Day  
This graph represents the graphical representation of the estimated least square means of Days 2 – 7 for 
each of the outcome groups. Day 1 SPCT results are used as a covariate in the statistical calculation of the 
means. The error bars represent the standard error for each day/outcome.  
 
value = 0.0134) and the SPCTC values decline from Day 2 to Day 7 (p-value = 0.0011). 
When comparing antibiotic use between the two groups, the TFS group had a SPCTC 
mean of 0.460 ng/mL (SE + 0.027) and DoT group had a SPCTC mean of 0.591 ng/mL 
(SE + 0.049). The two groups were statistically different with a p-value = 0.023. 
Summary 
 This chapter presented the descriptive and statistical analyses for each of the study 
objectives and hypotheses. Relationships between the serum procalcitonin concentrations 
and the biodata variables of the ALF and ALI subjects were explored. Procalcitonin did 
not appear to be a good indicator of infection as it did not adequately detect documented 
infections in the ALF subjects and was elevated when there was no documented evidence 
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of infection in this study. The data showed that in the presence of infection, SPCTC 
values increased as the severity of illness (determined by biodata and laboratory results). 
As noted, there were numerous cases of increased SPCTC values with no documented 
infection present. The SPCTC results appeared to be affected by physiologic factors 
associated with various ALF etiologies, particularly APAP toxicity. Changes in SPCTC 
values over time did appear to be a predictor of outcome with faster and larger decreases 
in SPCTC values in subjects who survived compared to slower and smaller changes 
noted for subjects who died or received a liver transplant. Interpretations of the three 
specific aims will be presented in the next chapter. The interpretations will be related to 
the results of the literature review. 
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CHAPTER FIVE:  DISCUSSION 
 
 This chapter presents a review of the results presented in Chapter Four. The 
results are presented in the context of the listed hypotheses, clinical implications and in 
comparison to the literature review. Limitations of the study are discussed as well as 
recommendations for future studies. 
Overview of the Problem 
 Infection and sepsis is a significant problem in the general population with 
mortality ranging from 10% for patients with SIRS to 50% for patients with septic shock 
(Brun-Buisson, 2000; Rangel-Frausto et al., 1995). ALF patients are particularly 
susceptible to infection for several reasons with a reported occurrence of 40% – 90% 
(Rolando et al., 2000; Vaquero et al., 2003). ALF and ALI patients have impaired 
immune function, are subject to invasive procedures, and have an increased chance of 
lung infections when chest physiotherapy and bronchial suction are contraindicated due 
to cerebral edema. Because of their extremely critical condition, the majority of ALF 
patients spend at least a portion of their hospital stay in the ICU. Studies have shown that 
admission to the ICU and use of devices (catheters, ventilators, invasive monitors, etc.) 
increase the risk of acquiring an infection (Clapperton, Rolando, Sandoval, Davies, & 
Williams, 1997; Rolando et al., 1990; Rolando et al., 2000; Stravitz, 2008; Suljagic et al., 
2005; Wade, Rolando, Philpott-Howard, & Wendon, 2003).
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 As was noted previously, identification of infection can be difficult and is time 
consuming. Therefore, finding a method that can quickly and reliably identify a bacterial 
infection is of great importance. It would be an added benefit if that method could also be 
used to guide antibiotic therapy. PCT has been shown in the general population to be a 
reliable marker of infection and is useful as a guide for antibiotic therapy. The purpose of 
this study was to determine if PCT could be utilized in the acute liver failure and acute 
liver injury populations to detect infection and by utilizing SPCTC levels, improve 
outcomes in this difficult situation. 
Discussion of the Study 
 Of the 1683 patients listed in the USALFSG ALF and ALI databases, 632 
subjects had an infection identified by standard bacterial culture techniques. This study 
was undertaken to determine if SPCTC could be used to identify bacterial infections 
sooner than standard bacterial culture in the ALF and ALI populations. Samples from 
patients in the ALF and ALI databases were obtained and SPCTC concentrations were 
measured to answer this question. While a study of SPCTC guided antibiotic therapy 
could not be accomplished using these retrospective samples, by looking at SPCTC 
results from serial samples of ALF patients based upon their outcome, this study 
attempted to determined if SPCTC values for subjects who achieved TFS differed from 
those who died or received a liver transplant. The study compared the differences in the 
SPCTC change over time in these two groups of patients.  
 As can be seen in the summary of the null hypotheses in Table 25, the results of 
this study were mixed. 
106 
 
 
 
Table 25:  Summary of Study Hypotheses 
NULL HYPOTHESES  
Expected  
Results  
Actual  
Results  
Specific Aim One  
H
0
:  There is no difference in SPCTCs between non-infected ALF/ALI 
patients, and non-infected chronic liver disease patients.  
Supported  Rejected  
H
0
:  There is no difference in SPCTSs between non-infected patients with 
liver disease (chronic and ALF/ALI) and the published PCT 
reference range (<0.1 ng/mL) for non-infected patients in the general 
population.  
Supported  Rejected  
H
0
:  There is no difference in SPCTC between ALF/ALI patients with 
different degrees of severity of infection (i.e., Neg SIRS, SIRS, 
sepsis, severe sepsis, and septic shock).  
Rejected  Rejected  
Specific Aim Two  
H
0
:  There is no difference in SPCTC in ALF/ALI patients between the 
first day a positive culture was collected and the three days prior to 
the positive culture.  
Rejected  Supported  
Specific Aim Three  
H
0
:  There is no difference in SPCTC between ALF and ALI patients with 
a bacterial infection/sepsis who have transplant free survival and 
those who die or receive a liver transplant.  
Rejected  Rejected  
H
0
:  There is no difference in changes in the serial SPCTCs between 
ALF/ALI patients with a bacterial infection/sepsis who have 
transplant free survival and those who die or receive a liver 
transplant.  
Rejected  Rejected  
 
Specific Aim One 
 In reviewing the data from this portion of the study, the SPCTC results varied 
between the different illness severity categories. The chronic liver disease patients’ 
SPCTC values were at or near the expected PCT level of <0.1 ng/mL for “normal” 
subjects with no infection, partially confirming the hypothesis:  
H0: There is no difference in SPCTSs between non-infected patients with liver 
disease (chronic and ALF/ALI) and the published PCT reference range (<0.1 
ng/mL) for non-infected patients in the general population. 
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While SPCTC results from cirrhotic patients in the literature (Bota,et al., 2005; Connert, 
et al., 2003; Spahr, et al., 2001; Viallon et al., 2000) are mixed, the data from this study 
indicate that PCT is not elevated in the presence of mild or inactive liver disease. 
However, the results of ALF subjects, where the liver disease is much more severe, were 
not as clear. 
 When looking at ALF subjects across the full SIRS spectrum (Neg SIRS, SIRS, 
sepsis, sever sepsis, and septic shock) in relation to the hypotheses for this portion of the 
study, there were significant differences between the severity and etiology categories.  
H0:  There is no difference in SPCTCs between non-infected ALF/ALI patients, 
non-infected chronic liver disease patients. 
H0:  There is no difference in SPCTC between ALF/ALI patients with different 
degrees of severity of infection (i.e., no infection, SIRS, sepsis, severe sepsis, and 
septic shock). 
As noted earlier in chapter four, when looking at the ALF subjects in the severity 
categories with no documented infection (Neg SIRS and SIRS) in this set of samples, 
there was a significant difference between both categories and the <0.1 ng/mL reference 
value and the chronic patients’ levels, but no significant difference between the two 
categories themselves. Thus, the milder severity of illness and presumably infection free 
categories displayed at least in many instances, values that approximated those 
observed in the presence of active bacterial infection. There were also significant 
differences between the sepsis category and the severe sepsis and septic shock categories, 
but not between Neg SIRS, SIRS, severe sepsis, and septic shock.  
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 Within the Neg SIRS and SIRS categories, there were 31 subjects who had 
SPCTCs of 1.62 ng/mL or greater. This value was determined from the ROC analysis. Of 
these subjects, 13 had indications of infection later during their hospital/study course that 
could have affected the SPCTC results. These indications ranged from cultures positive 
for yeast or fungus, bacterial infections one or more days after the day the tested sample 
was obtained, and other evidence of infection (i.e., pancreatitis, left lower lobe infiltrate 
on x-ray, tooth abscess, and VAP). Five subjects had positive bacterial cultures at some 
point in the seven day course of the ALF or ALI studies after the day the PCT was 
measured. It was noted earlier that there are many similarities between signs and 
symptoms associated with ALF and those associated with severe sepsis. These 
similarities may have resulted in a delay in identifying a bacterial infection. The possible 
confounders (except yeast/fungal infections) were not captured as a variable in the 
algorithm used to select samples. Therefore, they were not found until a closer 
examination of the subject case report forms (CRFs) was made to determine possible 
causes of the increased SPCTCs. Yeast and fungal infections are captured in the infection 
data but were eliminated from the dataset as bacterial infection was use as the indication 
for a positive culture. Five subjects had yeast/fungal infections during the course of the 
ALF study. There is evidence that yeast and fungal infections can cause an increase in 
SPCTCs, but these values on average are lower than those seen with bacterial infection 
(Dornbusch et al., 2005; Martini et al., 2010; Nakamura, Wada, Takeda, & Nobori, 
2009).   
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 The most interesting feature in this grouping of data was that the sepsis category 
had a median value of 0.69 ng/mL that was significantly lower than the 1.62 ng/mL 
calculated cutoff value. Surprisingly, the sepsis group levels were lower than the median 
values of the Neg SIRS and SIRS categories (1.59 ng/mL and 2.29 ng/mL, respectively). 
A closer examination of the subject CRFs for this category did not reveal any clear idea 
as to why the results from this category with proven infections were so much lower than 
the Neg SIRS and SIRS categories. There were two subjects with tracheal aspirate 
cultures that were in the category with minimal evidence of infection (yeast and WBCs), 
but removing them from the category does not change the median value.  
All but two of the subjects in the sepsis category (84.6%) received antibiotics, 
which may have been a factor in the lower SPCTC values for this category. However, all 
other categories had a high percentage of antibiotics use (Neg SIRS = 63.3%, SIRS = 
79.3%, Severe Sepsis = 81.5%, and Septic Shock = 81.2%) as well. There was no 
difference in antibiotic use across etiologies (APAP, viral, and other) based upon the 
results of the Fisher’s Exact test (p-value = 0.647). It must be noted that the timing of the 
antibiotic use in relation to the time/day that the serum samples were collected was not 
known. The study CRFs did not indicate when antibiotic prophylaxis or treatment was 
initiated or discontinued. 
When the results were examined based upon etiology, subjects with APAP 
toxicity demonstrated higher SPCTC levels than those with any other etiology within 
each group. Clinically, SPCTC values in subjects with APAP toxicity may not be 
indicative of infection. There is evidence that APAP toxicity activates macrophages, 
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resulting in the release of cytokines and proinflammatory regulators, including TNF that 
contribute to APAP induced liver injury (Dragomir, J. D. Laskin, & D. L. Laskin, 2011; 
Jaeschke, McGill, & Ramachandran, 2012) . While the exact origin and pathogenic 
pathway of PCT is still unknown, it has been suggested that PCT is produced by 
neuroendocrine cells in the liver while other data suggest that it is released by 
macrophages (Matzaraki, 2007). However, there is some evidence that the increase in 
PCT may be initiated by TNF and IL-1b (Whang, 1999; Domensch, 2001). The 
elevated PCT may be a result of the APAP toxicity itself, but the mechanism of the sterile 
inflammation remains unclear. The SPCTC levels increased as severity of disease 
increased suggesting that SPCTC may still provide useful information regarding 
outcomes for APAP subjects, regardless of the presence or absence of infection. If 
procalcitonin is to be useful in this population, the cut-off indicating infection may need 
to be set differently from the cut-offs of the general population and other ALF etiologies. 
This will have to be examined in future studies.  
 The median values of the last two categories, severe sepsis (3.46 ng/mL) and 
septic shock (5.89 ng/mL), were both well above the 1.62 ng/mL calculated cutoff and 
2.0 ng/mL literature cutoff for severe sepsis (Harbarth et al., 2001). These values were 
significantly different from the sepsis value of 0.69 ng/mL but not different from the Neg 
SIRS and SIRS category values. In these groups, only 7 of 27 severe sepsis subjects and 3 
of 16 septic shock subjects had SPCTC values less than the 1.62 ng/mL cutoff. As with 
the sepsis category, there is no obvious explanation for the decreased SPCTC values in 
the presence of an identified infection, except possibly the use of antibiotics. Only 5 of 27 
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severe sepsis subjects and 3 of 16 septic shock subjects did not receive antibiotics. Again, 
full bacterial culture reports were not available. The CRF did not contain information 
related to quantity of bacterial growth or antibiotic sensitivities that might have helped 
determine some of the differences among the various severity groups. 
 The SPCTC values of the ALF subjects when categorized by SIRS criteria appear 
to be similar to those obtained in the general population noted in the literature, as can be 
seen in Table 26. However, ALF Neg SIRS and SIRS values were higher than the 
literature values in all but one case (Giamarellos-Bourboulis), and might be a result of the 
severe liver damage, with or without bacterial infection. There have been some previous 
indications in the literature that PCT values may be increased in subjects with severe liver 
damage. Subjects with solid tumors that had metastasized to the liver had a higher mean 
PCT value than control subjects and those with non-metastasized solid tumors (Matzaraki 
et al., 2007). The sepsis and severe sepsis ALF results were similar to the literature 
reports while the septic shock results were lower than all but one of the literature reports 
(Brunkhorst et al., 2000; Castelli et al., 2004; E. J. Giamarellos-Bourboulis et al., 2002b; 
Harbarth et al., 2001; Oberhoffer, Vogetsang, Rubwurm, Hartung, & Reinhart, 1999).  
 In this study when SPCTC values were compared to AST and ALT values 
(indicative of the degree of liver damage) there were significant correlations. Spearman’s 
rho analysis produced a correlation coefficient of 0.229 (df = 111, p-value = 0.015) for 
AST and 0.192 (df = 110, p-value = 0.042) for ALT supporting the idea that SPCTC may 
be increased in severe liver disease even in the absence of infection.  
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Table 26:  Comparison of SPCTC Results by SIRS Category Between This Study and 
Previously Published Studies 
 
 ALF Giamarellos- 
Bourboulis 
Harbarth Castelli Brunkhorst Oberhoffer 
Mean / Median 
[ng/mL] 
Mean 
[ng/mL] 
Median 
[ng/mL] 
Neg SIRS /  
Not Infected 3.38 / 1.57 0.61 <0.2 0.14 na na 
SIRS 3.74 / 2.29 5.45 0.6 0.38 0.41 1.3 
Sepsis 5.43 / 0.69 7.29 3.5 3.0 0.53 2.0 
Severe Sepsis 11.99 / 3.46 6.26 6.2 5.58 6.91 8.7 
Septic Shock 13.14 / 5.89 38.76 21.3 13.1 12.89 39 
 
Missing data, might have led to false classification of subjects. Because the 
missing data were treated as negative values, subjects may have been classified in a 
severity category that was lower than the severity category they might have been 
classified in if all data were available.  
Specific Aim Two 
 The purpose of this portion of the study was to determine the utility of SPCTC as 
a screening biomarker for infection in ALF and ALI patients.  
H0:  There is no difference in SPCTC in ALF/ALI patients between the first day a 
positive culture was collected and the three days prior to a positive culture. 
Serial samples from 34 subjects were examined for this purpose. The selection process 
for this set of samples prescribed that there was no documented infection prior to the day 
of infection, which was the day of collection of a culture that resulted in growth of a 
bacterial pathogen. However, when the data were examined, there was no significant 
difference in SPCTC results between the four days (d-3, d-2, d-1, and DoI) with a 2 = 
6.741 (n = 34, df = 3, p-value = 0.081). There were individual cases for which the 
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SPCTC of the DoI increased over that of the D-3. Other cases within the category had 
higher SPCTC results on D-3 than those on DoI and other cases had low SPCTC results 
on D-3 that did not increase by DoI. When the subjects were sorted based upon the 
SPCTC from D3 and DoI, there is some indication as to possible reasons for the results 
that were obtained. The subjects were sorted based upon the following criteria: 
 Subgroup A samples, categorized based upon a D-3 level of > 3 ng/mL, had a 
decrease in the PCT values between D3 and DoI. As discussed earlier, there are several 
possible factors that may have affected the results. Subgroup A had the largest use of 
antibiotics (85.7%) of all of the subgroups (B = 50.0% and C = 75.0%) and antibiotics 
were more frequently used than for the whole group (73.5%). Based upon the literature 
(Christ-Crain et al., 2004; Schuetz et al., 2009), this may be an indication that there were 
unreported or unrecognized infections that antibiotics use were helpful in resolving. 
Again, there was no documentation of negative cultures to confirm a diagnosis of no 
infection and cultures were ordered at the treating physician’s discretion. Also noted, the 
majority of the cases with the highest SPCTCs were from the acetaminophen toxicity 
etiology. It is uncertain what the physiological process in the acetaminophen toxicity 
patients is that might result in higher SPCTC results than in other ALF etiologies or if 
these subjects had underlying infectious processes that went unrecognized. The later 
would seem less likely because APAP subjects tend to do well. The possible link of 
APAP toxicity resulting in increased SPCTC discussed earlier, seems a more likely 
explanation and will have to be examined in future studies. 
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 Subgroup B samples were categorized based upon a D-3 SPCTC level of <3 
ng/mL and increased by DoI. Overall, there was an increase in the SPCTC median values 
from 1.96 ng/mL (D-3), 1.99 ng/mL (D-2), 2.09 ng/mL (D-1), to 5.34 ng/mL (DoI). 
While the D-3 median SPCTC was above the 1.62 ng/mL cutoff calculated earlier, the 
SPCTC increased to above the literature documented 2.0 ng/mL cutoff for severe sepsis 
(Harbarth et al., 2001) by D-2. The SPCTC increased further by D-1 and DoI. This group 
also had the lowest usage of antibiotics and only contained 25% APAP etiology. This 
small subset of cases, counter to the other results, would support the idea that SPCTC can 
be indicative of an infection even prior to DoI, similar to results seen in the general 
population (Guven et al., 2002; Brunkhorst et al., 1999; Luyt et al., 2005). 
 Data from Subgroup C, categorized by having a D-3 result of <1.62 ng/mL, the 
calculated cut-off value, and decreased or remained below the cut-off by DoI, was the 
least interpretable of the subgroups. While 75.0% of this group had been prescribed 
antibiotics possibly suppressing bacterial growth, their antibiotic use was not different 
from antibiotic use by the whole group (73.5%). Again, there was insufficient 
information concerning bacterial growth and antibiotic sensitivity and dose 
administration to fully understand the results obtained. There were no other striking 
features of the group with the exception, that over half of the group has ALF etiologies in 
the “other” category (i.e., anything other than acetaminophen toxicity and viral hepatitis). 
Again, it is unknown how much, if any, affect ALF etiology had on the SPCTC values. 
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 Overall, data from this group of subjects did not support the use of SPCTC as a 
predictor of infection. However, it could be argued that SPCTC results for Subgroups A 
and B were indicative of infection. Subgroup A may have had undetected infections at or 
prior to D-3 and SPCTC predicted infections in Subgroup B at or before DoI. Future 
controlled studies will be needed to better understand how useful SPCTC is in detecting 
infection in ALF and ALI patients. 
Specific Aim Three 
 The purpose of Specific Aim 3 was to determine if changes in the SPCTC of ALF 
and ALI patients with a confirmed bacterial infection on day one would predict the 
outcome of the patients – either TFS or DoT. 
 H0:  There is no difference in SPCTC between ALF/ALI patients with a bacterial 
infection/sepsis who have transplant free survival and those who die or receive a 
liver transplant. 
H0:  There is no difference in the changes in the serial SPCTCs between ALF/ALI 
patients with a bacterial infection/sepsis who have transplant free survival and 
those who die or receive a liver transplant. 
Serial samples from 47 subjects, 26 with TFS and 21 with DoT outcomes, were tested to 
determine the SPCTCs. The largest difference between the two groups is that 73.1% of 
the TFS group had APAP etiology while 76.2% of the DoT group had etiologies other 
than APAP and viral hepatitis. This overall difference in etiologies fits with the outcomes 
based upon etiology in the literature (Lee & Seremba, 2008) in which APAP etiology has 
a survival rate of 58% to 64% compared to only about 20% to 25% survival for other 
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etiologies including drug-induced, autoimmune, and indeterminate ALF. Use of 
antibiotics was also slightly higher in the DoT group 85.7% compared to 69.2% for the 
TFS group. Despite these differences, when etiology (APAP vs. Other Etiologies) was 
examined as a potential covariate in the statistical model, it was not significant. 
Prophylactic antibiotic use alone and antibiotic therapy alone were not significant. Coma 
grade (1 – 2 vs. 3 – 4) was also examined, for significance to the model. The distribution 
of coma grades between the TFS and DoT groups was similar and there was no 
significance in the statistical model. While infection is associated with higher HEs, higher 
HEs are also associated with lower rates of spontaneous survival (Vaquero, 2003). The 
lack of difference between coma grade and the two groups may be attributed to the 
differences in etiology. While both groups have similar coma grade results, APAP has a 
better survival rate than other etiologies, even in the presence of higher coma grades and 
infection (Vaquero, 2003).     
 The only other differences noted, were an increase in the bilirubin and lactate 
values on DoI (Day 1) in the DoT group when compared to the TFS outcome group. 
Although there were no other significant differences in other indicators of liver function 
(i.e., AST, ALT, and INR), the bilirubin and lactate differences may be a function of the 
differences in etiologies or the severity of the liver disease.   
 The composite data from this portion of the study would suggest that there was 
little difference in SPCTC values between the two outcome groups. However, on closer 
examination, the median SPCTC values for the TFS group (which had a large percentage 
of APAP cases – 73.1%) were higher than the DoT group (76.2% etiologies other than 
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APAP) median SPCTC values. Both groups demonstrated elevated median values on Day 
1, TFS = 2.90 ng/mL and DoT = 1.42 ng/mL, however, the median SPCTCs for the TFS 
survival group decreased faster than those for the DoT group. When the use of antibiotics 
was factored into the results, the difference between the two groups was even more 
apparent (see Figure 15 above). These results were similar to those reported in the 
literature by others (P. E. Charles et al., 2009) when looking to use of PCT to guide 
antibiotic therapy. In the PCT guided antibiotic therapy study, the decrease in SPCTCs in 
patients who received appropriate antibiotic therapy was larger than the decreases seen in 
patients who did not receive appropriate therapy. It cannot be determined from our data 
whether appropriate antibiotic therapy was used because the ALF CRFs did not include 
full microbiology reports with antibiotic sensitivities or specific information documenting 
when a specific antibiotic therapy was initially given. However, when the SPCTC 
profiles from the two studies are compared, the TFS group had a profile similar to the 
“appropriate use of antibiotics” profile, while the DoT profile was similar to that of 
subjects who received “inappropriate antibiotic therapy” (or those who did not respond to 
therapy). It would appear that ALF subjects with a documented infection who have a 
larger and faster decrease in SPCTC have a better outcome (i.e., TFS) than subjects 
whose SPCTC do not decease as much or as rapidly (DoT group). However, further study 
in which antibiotic use and etiology are controlled for will be required to confirm these 
findings. 
 
 
118 
 
 
 
Conclusions 
 Procalcitonin has proven to be useful in detecting and monitoring treatment for 
infection and sepsis in the general population. While the results of this study were 
hampered by factors that could not be totally controlled for or eliminated, there are some 
important conclusions that can be made. High SPCTC values in ALF subjects are not 
indicative of bacterial infection in many cases. While there were cases of high SPCTC 
values in the presence of infection, there were some subjects who had a high SPCTC but 
did not have a documented infection to justify the high SPCTC result. Further elucidation 
of the relationship between increased SPCTC and severe liver disease, particularly acute 
liver damage such as that resulting from APAP toxicity, is required. In addition, the 
SPCTC values do appear to fall in the presence of antibiotic therapy in patients who 
achieve transplant free survival but may also have simply been the result of the recovery 
process itself.  
 What was not answered clearly is ‘What is the best cut-off value to indicate the 
presence or absence of a bacterial infection in this unique patient population?’ The results 
of the study were confounded by the presence of antibiotics, missing data, and small 
sample sizes in some categories, despite the fact that this study utilized the largest 
collection of data and samples ever amassed for this rare condition. While a cutoff of 
1.62 ng/mL was calculated for the ALF/ALI population, the sensitivity (the ability of a 
test to detect an infection in the presence of the infection) and specificity (the ability of a 
test to not detect an infection when an infection is not present), 64.3% and 62.0% 
respectively, were lower than those obtained in general population studies. When a ROC 
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analysis was performed on non-APAP results, the cut-off remained the same (1.62 
ng/mL), but sensitivity decreased (54.3%) and specificity increased (69.2). Whether these 
changes reflect the differences in etiology or were a result of a smaller sample size, will 
have to be determined by later studies. In a study by (Harbarth et al., 2001), a 97% 
sensitivity and a 78% specificity were obtained at a cutoff of 1.1 ng/mL. Strong evidence 
was provided that etiology affects these results. The sample size of the various etiologies 
was too small for a clear determination of this effect. Further studies are needed to 
discern the true utility of procalcitonin adequately in the acute liver failure population.  
 Infection was not readily detected in all cases. While in a small subset of subjects 
infection was marked by an increased the SPCTC value on the DoI, other subjects had 
increased SPCTC values up to three days (this was the maximum amount of time studied) 
prior to the DoI while other subjects no elevated SPCTCs prior to or on the DoI. Again, 
this is an indication that SPCTC may not be useful in this population.  
 The one promising aspect of this study was the fact that SPCTC values over time 
were suggestive of outcome. SPCTC values that had a larger and faster decrease over 
time were indicative of TFS while, slower, smaller decreases were indicative of DoT.  
Limitations of the Study 
 The use of retrospectively collected data and samples allowed for a relatively 
quick completion of this study despite the small target population, but it was also the 
greatest limitation to this study. The acute liver failure databases are prospectively 
collected studies designed to study acute liver failure not bacterial infection. The low 
incidence of acute liver failure in the US (approximately 2500 cases per year) makes 
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studying ALF challenging. The number of different etiologies confounds this even more. 
In addition, only about 30% of the ALF cases (based upon the number of documented 
infections in the USALFSG acute liver failure and acute liver injury databases) have a 
documented infection.  
 While this large retrospective database allowed for quick examination of many 
types of problems affecting patients with ALF, there were factors that had to be 
addressed. The ALF and ALI databases contain a large amount of missing data. The 
databases were prospectively collected observational studies. This means that the 
database and biosample repository were compiled from available data and samples. 
Unlike a clinical trial in which data and samples are collected at prescribed times, an 
observational study relies on available data. ALF subjects may not have certain labs or 
samples collected for a variety of reasons: labs not ordered, dis-enrolled because of liver 
transplant, death, and protocol changes over the course of the 10+ years of the ALF study 
changed what information was collected on the CRFs. Another reason for missing 
samples was that the supply of aliquots of samples from certain time-points was depleted.  
 All of these factors undoubtedly affected the results of this study. Missing data 
may have affected how samples were classified. The SCCM/ESICM/ACCP/ATS/SIS 
International Sepsis Definitions Conference included a long list of biodata parameters 
that can be used to classify patients along the SIRS continuum. While many of the ALF 
and ALI parameters recorded in the CRFs of ALF and ALI subjects are among those 
identified by the sepsis conference, many other parameters that could have been used 
were not routinely recorded. Of those that were routinely collected, some were not 
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collected on each day of the study. For this reason, subjects in the study were classified 
based upon available data. This meant that subjects may have been mis-classified. An 
example –a subject classified in the sepsis category should actually have been in the 
severe sepsis or septic shock category because laboratory parameters that would have 
changed the classification were missing. The best option would be not to use this subject, 
but a review of the available data showed that of the 12,492 patient days, for the 1863 
subjects of this study, available for use in this study only 3% of the all days for all 
subjects had complete data. The study could not have been accomplished with only 3% of 
the database available. Therefore, to maximize the sample availability, use of subjects 
with missing data was allowed. In Specific Aim One, for the purpose of classifying 
subjects, missing values were treated as negative values. 
 Missing data did not change the status of samples in the SIRS and septic shock 
categories because samples in the categories were included only if specific criteria were 
met. Neither a positive nor a negative value for any missing data changed the result of a 
sample included in these two categories. However, missing data may have affected the 
sepsis and severe sepsis categories. If a sepsis sample had missing data that had a positive 
result, it could mean the sample should have been in the severe sepsis group (or severe 
sepsis should have been in the septic shock group). However, it is unclear whether the 
sepsis and severe sepsis groups can be clearly separated in the ALF population because 
by definition all septic ALF patients should have been considered in the severe sepsis 
category because of the liver failure. The attempt to separate these two groups was to 
show a progression of severity. By allowing samples with missing data to be categorized, 
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sample availability was maximized for categories with fewer available samples. The non-
infected category was filled with subjects who are negative for SIRS and do not have a 
documented infection.  
 Limited availability of samples in the sample repository also affected all sections 
of this study. The sepsis and septic shock categories in the Specific Aim One section had 
less than half of the samples requested for the study. Part of the problem with these 
categories, was there were more subjects with available biodata than had available serum 
samples. This was also true for Specific Aims Two and Three. Specific Aim Two was 
limited to 34 subjects from a requested 45 due to limited availability of sample aliquots. 
Specific Aim Three was limited to 47 subjects from a requested 60. 
 Missing data and samples also affected how the results were analyzed. In Specific 
Aims One and Three, the analyses used were adjusted to account for missing data. In 
Specific Aim One, data related to etiology were not analyzed because in the cases of the 
sepsis and septic shock categories and the viral hepatitis group, there were not enough 
samples to provide an adequate statistical analysis. In the case of Specific Aim Three, a 
mixed methods analysis of covariance was used instead of a standard ANOVA and/or 
ANCOVA. The mixed methods approach allows for the missing data without losing 
degrees of freedom. 
 The ALF databases were not primarily designed to study infection. A prospective 
study designed to examine the use of SPCTC as a biomarker of infection, would control 
for antibiotic use, collect complete culture and sensitivity reports, and collect laboratory 
results relevant to correct classification to the subjects. This was not the case in the ALF 
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databases. While antibiotic use (both prophylaxis and therapy) was captured, dates and 
times of initiation of antibiotics were not captured. Also only minimal culture 
information was collected (i.e., culture type, day of the study the culture was collected, 
and organisms reported). No sensitivity information relevant to the pathologic organism 
was collected. Collection of cultures was based upon physician discretion and not under 
set conditions. Infection was determined as present in all parts of the study only if a 
positive culture was present. It was possible that an infection was present, in the 
population but was not found by standard culture techniques and therefore not 
documented. All of these factors affected the ability to interpret the results of this study 
correctly.  
 Another limitation of the use of retrospective samples from the ALF repositories 
was the age of the samples. There is evidence that long-term storage of samples results in 
a decrease in the SPCTC results. Schuetz, et al. (2010) studied two sets of samples that 
were store at -80
o 
C for 4.8 to 5.5 years and 3.3 to 4.6 years. The SPCTCs for each set 
decrease by 11.4% and 13.5% respectively. ALF samples used in this study, were stored 
an average of approximately 6.75 years at -80
o 
C storage. While it is assumed, that the 
length of time in storage has decreased the SPCTCs obtained, the exact amount of 
decrease is unknown and an estimate of the extent of the effect cannot be calculated. The 
assumption made for this study was that the affect is equal for all samples but in reality, 
this is probably not the case. 
 The use of the ALF databases addressed a potential threat to external validity. The 
databases collect samples from subjects enrolled in the studies from medical centers 
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across the US. The USALFSG has 13 active clinical sites. Prior to 2010, there were a 
maximum of 23 clinical centers in the study. All of the clinical sites are major 
medical/academic centers. Because smaller medical facilities are not included in this 
study, this could be considered a threat to external validity. However, due to the severity 
of illness presented by patients with ALF, many of these patients were transferred to 
larger facilities to take advantage of a possible liver transplant (to date - the only 
approved treatment for ALF other than supportive care) (Bower et al., 2007).  
 The one threat to external validity that has not been addressed by this study was 
the use of only one PCT testing platform and only one instrument on that platform. To 
date, FDA approval is limited in the US to the BRAHMS KRYPTOR and bioMérieux 
Clinical Diagnostics Vidas analyzers. These platforms were not available for use in this 
study. Siemens Healthcare Diagnostics has developed the ADVIA Centaur BRAHMS 
PCT assay that is currently in the FDA approval for use process but has not received final 
approval. The assay has been approved for use in the European Union. The ADVIA 
Centaur PCT assay has shown good comparison to the KRYPTOR PCT assay. Despite 
the fact that BRAHMS licenses all available assays, there is no standardization between 
the assays. Due to the limited sample volume for each serum aliquot, only one result for 
each sample was obtained and all samples for this study were tested on one analyzer. All 
of these factors allow for potential differences in results if this study were to be repeated 
on a different instrument or assay system.  
 
 
125 
 
 
 
Recommendations for Future Studies 
 Despite the valuable information provided by this study, the best method to 
answer the questions left unanswered by this study would be a controlled clinical trial of 
prospectively enrolled subjects. A clinical trial with controlled conditions would diminish 
or eliminate the effect of many of the problems encountered in this study. A prospective, 
controlled clinical trial could: 
 establish minimum sample sizes for all categories (i.e., severity of illness, 
etiology, outcome, etc.) 
 control the use of antibiotics – which antibiotics were used, documentation of 
times of antibiotic initiation and discontinuation, availability of antibiotic 
sensitivities for the identified bacterial organism to determine appropriateness of 
prescribed antibiotics, and guidelines for antibiotic prophylaxis and therapy;  
 screen for the presence or absence of bacterial infections;  
 inclusion/exclusion criteria to provide a better categorization of subjects within 
the study;  
 limit the amount of missing data – specific biomarkers and laboratory values 
would be collected for all subjects at all specified times; and 
 limit missing samples – appropriate samples and sample volumes would be 
collected for all subjects for all required time points. 
 Procalcitonin has been described as a “homokine”, a protein that has some 
characteristics of a hormone and some characteristics of a cytokine. Cytokine results vary 
greatly depending upon disease and immune response. This study did not have enough 
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sample size to study this. Based upon the results of this study, a closer look at different 
ALF etiologies in relation to SPCTC values in the presence and absence of infection may 
prove useful. There was some indication in this study, that SPCTC results in subjects 
with acetaminophen toxicity may be different from the SPCTC results from other 
etiologies. A prospective study with a larger sample size in which determination of 
infection and antibiotic use in a comparison of acetaminophen toxicity vs. non-APAP 
ALF patients should be studied to adequately determine if APAP toxicity affects the 
procalcitonin results.  
A prospective, controlled study could potentially identify the best SPCTC cut-off 
value(s) for identifying infection and sepsis in ALF patients (and if necessary specific 
populations within ALF such as APAP toxicity) which could speed the identification of 
bacterial infection and sepsis in this critically ill population. It could determine the utility 
of antibiotic guided therapy in ALF which could shorten exposure to hepatotoxic drugs 
and eliminate unnecessary prophylaxis. And, it would provide more information 
regarding the relationship between PCT and severe liver disease, particularly APAP 
toxicity.  
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Appendix A: Algorithms to determine SIRS category for Specific Aim One samples 
1 = Yes 0 = No 
 
SIRS - If column I has a value of 1, the sample is categorized as positive for SIRS. 
 
 
Sepsis  - If column L has a value of 1, the sample is categorized as positive for Sepsis. 
 
 
 
 
 
 
 A B  C D E F G H I  
 Temp 
   
pCO2 WBC 
  
  
 <36 >38 Sum Temp <32 >12 <4   SIRS 
 
IF 
 A<36=1 
otherwise =0 
IF  
A>38=1 
otherwise =0 A + B 
IF  
C=1, then 1 
otherwise =0 
IF E<32=1 
otherwise =0 
IF  
F>12=1 
otherwise =0 
IF  
G<4=1 
otherwise =0 
D+E+ 
F+G 
IF 
 H>1, then 1 
otherwise =0 
Sample# 0 0 0 0 0 1 0 1 0 
 J K L 
 Infection Infection 
   +  SIRS SEPSIS 
 
Infection =1, 
No infection =0 I + J 
IF  
K>1, then 1 
otherwise =0 
Sample# 1 1 1 
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2
 
Severe Sepsis - If column AF has a value of 1, the sample is categorized as positive for Severe Sepsis. The group doesn’t  
 include patients with only liver failure in the group for septic shock. Patients with only liver failure will be 
 included in the sepsis category. 
 
 
 
 
 
 
 
 T U V W X Y Z 
 INR Platelet Bilirubin Lactate MAP 
 
HE / CG 
 >1.5 <100,000 >4 >1   <70   
 
IF  
T>1.5=1 
otherwise =0 
IF 
U<100=1 
otherwise =0 
IF  
V>4=1 
otherwise =0 
IF  
W>1=1 
otherwise =0 
 
IF Y<70=1 
otherwise 
=0 
 Sample# 1 0 1 0 71 0 1 
 
 
 M N O P Q R S 
 pO2/FiO2 
 
Creatinine -  
 
Acute Renal Failure 
     
previous 
Creatinine >0.5 ARF Adm Dialysis ARF 
 
 
IF 
 M<300=1 
otherwise =0 
 
IF 
 O<0.5=1 
otherwise =0 
  
IF  
P, Q, OR  
R >0 =1, 
otherwise =0 
Sample# 281 1 -0.50 0 0 0 0 
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 AA AB AC AD AE AF AG 
 
with liver 
components 
 
Severe 
without liver 
components   Severe Compare  
 N+S+T+U+ 
 
Sepsis N+S+U+ 
 
Sepsis AC to  
 V+W+Y+Z  
 
w Liver W+Y    wo Liver AF 
  
IF 
 AA>0, then 1 
otherwise =0 
IF  
L+AB=2, =1, 
otherwise =0 
 
IF  
AD>0, then 1 
otherwise =0 
IF  
L+AE=2, =1, 
otherwise =0 
IF  
AC=AF, =1, 
otherwise =0 
Sample# 4 1 1 1 1 1 1 
 
 
Septic Shock - If column AK has a value of 1, the sample is categorized as positive for Septic Shock. 
 
 AH AI AJ AK 
 D1 
 
 Septic Shock 
 MAP 
 
Pressor 
therapy 
map+prss+ 
 <60 
 
sepsis 
 
 
IF  
AH<60=1 
otherwise =0  
IF  
L+AI+AJ=3, =1, 
otherwise =0 
Sample# 55 1 1 1 
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